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ABSTRACT OF THE DISSERTATION

Type 1 and F17-like Pili Promote the Establishment of the Uropathogenic E. coli Intestinal
Reservoir.
By
Caitlin N. Spaulding

Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Microbiology and Microbial Pathogenesis
Washington University in St. Louis, 2017
Dr. Scott J. Hultgren, Chair

Urinary tract infections (UTI) affect over 150 million individuals worldwide every year.
These infections are associated with significant morbidity and have a sizeable economic impact,
with $5 billion being spent on UTI treatment in the USA annually. Uropathogenic E. coli
(UPEC) are responsible for 80% of community acquired UTIs and 65% of nosocomial UTI. The
current standard of care for UTI is antibiotic therapy. However, 30-50% of women experience
recurrent UTI (rUTI) despite receiving antibiotic therapy. The prevalence of single and multidrug resistant UPEC strains has led to increased reliance on carbepenems, which are primarily
reserved for multi-drug resistant infections, to treat an increasing number of patients.
Consequently E. coli strains resistant to colistin, a drug of last resort for treating carbapenemx

resistant Enterobacteriaceae, have now been isolated in over 30 counties. The rate at which drugresistant E. coli are spreading across the globe emphasizes the urgent nature of the antibioticresistance crisis we currently face and the dire need for new, antibiotic-sparing therapies that
target UPEC virulence factors. To colonize host tissue, E. coli encode chaperone usher pathway
(CUP) pili and single UPEC strains can encode up to 16 distinct CUP pilus operons. Although
CUP pilus types that promote UPEC colonization of the urinary tract have been identified, no
studies investigating a role for CUP pilus types in UPEC intestinal colonization have been
published. Still, leading models of infection posit that UPEC in the gut seed UTI by being shed
in the feces, and then colonizing the peri-urethral or vaginal tissue and subsequently ascending
through the urethra to access the bladder. Using a mouse model of UPEC intestinal colonization I
found that two (CUP) pili, F17-like pili and type 1 pili, provide a fitness advantages for UPEC in
the gut. The X-ray crystal structure of the F17-like pilus adhesin lectin domain, coupled with
molecular studies of glycan binding, disclosed a ligand specificity distinct from other pilus types
known to facilitate gastrointestinal colonization. While phylogenomic studies revealed that F17like pili are closely related to pilus types carried by intestinal pathogens, but are restricted to
extra-intestinal pathogenic E. coli. Moreover, I found that high-affinity mannose analogues
(mannosides) that target the function of type 1 pili and effectively treat UTI reduce intestinal
colonization by clinical UPEC isolates, including a multi-drug resistant strain, without disrupting
gut microbiota structure. By decreasing the intestinal UPEC reservoir that seeds bladder
infection, mannosides could significantly reduce the rate of UTI and rUTI. Further, mannosides
act like a molecular scalpel, specifically targeting intestinal UPEC with minimal effects on the
overall gut microbiota. Ultimately, therapies like mannosides, which selectively target
colonization by a specific pathogen, have potential to revolutionize treatment and prevention of
xi

rUTI. Take together, this dissertation provides invaluable tools and insights into the understudied
UPEC intestinal reservoir

xii

Chapter 1: Adhesive Pili in UTI Pathogenesis
and Drug Development
From:
Adhesive Pili in UTI Pathogenesis and Drug Development
Caitlin N. Spaulding and Scott J. Hultgren

Pathogens 2016, 5(1), 30. doi: 10.3390/pathogens5010030. PMID: 26999218
Copyright © 2016, Molecular Diversity Preservation International (MDPI). All Rights Reserved.

Abstract
Urinary tract infections (UTIs) are one of the most common bacterial infections, affecting
150 million people each year worldwide. High recurrence rates and increasing antimicrobial
resistance among uropathogens are making it imperative to develop alternative strategies for the
treatment and prevention of this common infection. In this Review, we discuss how understanding
the: (i) molecular and biophysical basis of host-pathogen interactions; (ii) consequences of the
molecular cross-talk at the host pathogen interface in terms of disease progression; and (iii)
pathophysiology of UTIs is leading to efforts to translate this knowledge into novel therapeutics
to treat and prevent these infections.
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Introduction
Urinary tract infections (UTIs) can be acquired in the community or hospital setting and are
one of the most common bacterial infections that occur, affecting more than 150 million people
worldwide each year [1–3]. UTI is clinically divided into two major infections, characterized by
the localization of the bacteria in the urinary tract, cystitis and pyelonephritis. Cystitis, or lower
UTI, is infection of the bladder. Once in the bladder, bacteria can ascend the ureters and colonize
the kidneys, causing pyelonephritis or upper UTI. While the incidence of pyelonephritis is fairly
low (~0.3%–0.6%) it is particularly dangerous as uncontrolled bacterial infection can spread to
the bloodstream, causing sepsis (which occurs in ~2% of pyelonephritis cases) [4,5]. UTIs are
also categorized as uncomplicated or complicated infections. Complicated UTI occurs in patients
with: (i) functional or structural urinary tract abnormalities; (ii) renal failure; (iii)
immunosuppression; (iv) pregnancy; and/or (v) foreign bodies, such as indwelling catheters,
placed within their urinary tract [6–8]. Catheter-associated UTIs (CAUTI), make up 70%–80%
of all complicated UTI and are the most common type of nosocomial infection [4,9]. CAUTI are
of particular concern as they result in high morbidity, increased mortality and are the most
common cause of secondary sepsis in hospital patients. While complicated UTI affects
individuals of both genders, uncomplicated UTI primarily affects otherwise healthy women [10].
Pyelonephritis often occurs in healthy, non-pregnant women but can be categorized as a
complicated UTI because of the potential of developing a blood stream infection. For women,
the lifetime risk of developing an uncomplicated UTI approaches 60% [5]. Of these women who
2

experience an initial UTI, 20%–30% will go on to experience a recurrent infection (rUTI) within
4–6 months, despite receiving appropriate antibiotic therapy [5,11]. To combat rUTI, these
women are treated with frequent antibiotic therapy often to be taken at the time that symptoms
arise or immediately following sexual intercourse [6]. However, a subset of these women will
continue to experience rUTI as frequently as six or more times a year [12]. Due to its prevalence
and high rates of recurrence, UTI is associated with significant economic costs. The financial
burden of UTI in the United States, which reflects both direct medical costs and indirect costs
such as lost work output and wages, is an estimated $5 billion annually [5]. These infections also
result in significant patient morbidity resulting in serious deterioration in quality of life
including: pain, discomfort, disruption of daily activities, and few treatment options other than
long-term antibiotic prophylaxis [5,11,13].
While many bacterial organisms cause UTI, the most common causative agent of both
uncomplicated and complicated UTI is the gram-negative pathogen uropathogenic Escherichia
coli (E. coli) (UPEC). UPEC are responsible for 80%–90% of all uncomplicated UTI and
approximately 65% of complicated UTIs [5,14,15]. Gram-positive Enterococcus species are the
second leading cause of complicated UTI (11%) and the third leading cause of uncomplicated
UTI (5%) [15]. The source population of UPEC and Enterococcus that lead to UTI is thought to
be the gastrointestinal tract, where they can reside as either commensal or transient members of
the gut microbiota [11,16,17]. When present in the gut, UPEC or Enterococcus spp. can be shed
in the feces, inoculating peri-urethral or vaginal areas, and are subsequently introduced into the
urinary tract during periods of physical manipulation such as during sexual activity or
catheterization (Figure 1A) [18]. Upon entering the bladder, uropathogens must bind to an
available epithelial receptor and/or, if present, abiotic-surface to establish and maintain
3

colonization. UPEC and enterococcal species both accomplish this through the expression of
distinctive adhesive pili on their surface. After creating a foothold in the bladder, uropathogens
employ a myriad of additional virulence factors to establish bladder colonization in the face of an
active immune response, micturition, and rapid epithelial cell exfoliation. Historically, antibiotics
have been used, very successfully, to treat patients with UTI. However, the rise of single and
multi-drug resistant uropathogens as well as high rates of recurrence in women infected with
both antibiotic sensitive and drug-resistant uropathogens has become a major concern,
highlighting the need to develop alternative strategies to treat patients with UTI and CAUTI. In
this review, we will discuss the role of adhesive pili during UTI or CAUTI. Here we will focus
mainly on UTI and CAUTI caused by UPEC and Enterococcus spp. due to the high prevalence
of these pathogens in community-acquired and nosocomial infections. We will also explore the
development of alternative, non-antibiotic treatment strategies that target adhesive pili in order to
prevent UPEC and Enterococcus spp. from initiating infection and thus causing disease.

The Role of Chaperone-Usher Pathway (CUP) Pili in UPEC Mediated UTI
CUP Pilus Assembly Mechanisms
Upon entering the bladder, UPEC must first adhere to the bladder epithelium, also referred
to as the urothelium, or risk clearance during urine voiding. Recognition and attachment to host
and environmental surfaces is mediated through the expression of non-flagellar, adhesive,
extracellular fibers, called pili that bind to receptors present on the host cell surface. In UPEC,
many of these adhesive pili belong to a large, conserved family of pili called the chaperone-usher
pathway (CUP) pili [20]. CUP pili are assembled by the corresponding chaperone-usher
machinery, which are encoded by operons that contain all the dedicated genetic information
4

necessary to assemble a mature pilus: an outer-membrane pore-forming usher protein, a
periplasmic chaperone protein, pilus subunits, and in most cases, a tip adhesin protein. The first
crystal structure of a CUP chaperone, PapD, which is involved in the assembly of P pili, revealed
that it consists of two-immunoglobulin (Ig) domains [21]. Two key amino acid residues, R8 and
K112, present in the cleft of the chaperone were subsequently identified as the active site of the
protein [22]. Unlike the chaperone, pilus subunits are composed of an incomplete Ig fold, which
lacks the C-terminal beta strand and requires the assistance of the dedicated chaperone for
folding and stability (Figure 2B,D). Chaperone-assisted folding occurs by a reaction termed
donor strand complementation (DSC) in which conserved alternating exposed hydrophobic
residues on the chaperone’s G1 strand are buried in complementary pockets in the pilus subunit,
allowing for the completion of the subunits Ig fold (Figure 2C) [23,24]. This interaction allows
pilus subunits to fold into a primed, high-energy state in complex with the chaperone, ultimately
allowing the subunits to be targeted to the outer membrane usher (Figure 2E). The usher, a gated
channel, is made up of five functional domains: a 24 stranded transmembrane β-barrel
translocation domain (TD), a β-sandwich plug (PLUG) that resides in the pore of the TD in the
apo-usher, an N-terminal periplasmic domain (NTD) and two C-terminal periplasmic domains
(CTD1 and 2) [25–29]. The usher catalyzes pilus assembly by driving subunit polymerization in
a concerted reaction termed donor strand exchange (DSE) (Figure 2E,F) [30–33]. Pilus subunits,
excluding the adhesin, encode an N-terminal extension (Nte) comprised of conserved alternating
hydrophobic residues. DSE occurs when the chaperone is displaced and an incoming subunit’s
Nte zips into the previously chaperone-bound groove of a nascently incorporated subunit at the
growing terminus of the pilus. This “zip-in-zip-out mechanism” allows for the final folding of
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the pilus subunit, such that every subunit in the pilus completes the Ig fold of its neighbor
(Figure 2F).

The Role of Type 1 Pili during Uncomplicated UTI
A hallmark of the luminal surface of urothelial cells, also called superficial facet cells, are
the presence of uroplakin plaques, which consist of 4 uroplakin integral membrane proteins, that
function as a barrier between the toxic contents of the bladder and the underlying urothelium
[34,35]. The surface of the uroplakin is studded with mannose [36,37]. The tip adhesin for type 1
pili, FimH, binds mannose with stereochemical specificity. Therefore, upon entering the bladder,
FimH is able to bind mannosylated residues on the bladder surface, such as those found on
uroplakin as well as β1-α3 integrin receptors (Figure 1B) [36,38–40]. FimH mediated interaction
with the urothelium induces a signaling cascade that activates Rho family GTPases and results in
actin rearrangement within urothelial cells, promoting UPEC invasion (Figure 1C,D) [38,41,42].
Studies in mice have revealed that once inside superficial facet cells, UPEC are able to escape
the endocytic vesicle, via unknown mechanisms, into the cytoplasm where they replicate rapidly
forming biofilm-like communities called intracellular bacterial communities (IBCs) (Figure
1D,E) [43–45]. In mice, type 1 pili are not only required for cellular adherence and invasion but
also for the aggregation of bacteria into an IBC in the host cell cytoplasm [46]. Mouse studies
have shown that invasion is a critical step in UPEC pathogenesis in naïve mice, allowing the
bacteria to rapidly replicate in a niche protected from many innate immune defense mechanisms
and antibiotics. UPEC that cannot invade the urothelium, like those lacking FimH, are quickly
cleared from the bladder, emphasizing the importance of this intracellular stage to the success of
the pathogen [46]. Mature IBCs contain approximately 104 bacteria. Upon maturation, bacteria
6

within the IBC adopt a filamentous morphology and disperse from the biomass, fluxing out of
the cell and back into the bladder lumen where they can adhere to and/or invade adjacent facet
cells or exposed transitional epithelial cells (Figure 1G,H) [43,44,47,48]. Importantly, evidence of
IBCs and bacterial filaments have been observed in women suffering from acute UTI, one to two
days post self-reported sexual intercourse, but not in healthy controls or infections caused by
Gram-positive organisms, which do not form IBCs [49]. IBCs have also been observed in urine
from children with an acute UTI and their presence was correlated with recurrent UTI,
supporting the validity of their importance in pathogenesis and the ability of the mouse model to
recapitulate human disease [50].
While the collection of tissue biopsies from women with UTI is generally contraindicated,
one study of tissue biopsies demonstrated the presence of intracellular UPEC [51]. In urine from
UTI patients and/or mice, the expression of type 1 pili has been reported to be variable [52–54].
Several studies, in mice and humans, have demonstrated that UPEC attached to shed epithelial
cells in the urine express type 1 pili while planktonic UPEC found in the urine tend to be
nonpiliated [54,55]. This suggests that the expression of type 1 pili is niche specific, with type 1
pili being expressed by UPEC that are attached to the epithelial surface.
In addition to type 1 pili, a mosaic of UPEC virulence factors including adhesins, toxins,
capsule, siderophores, and flagella have been identified and characterized [39,56–61]; however
the direct contribution of these putative urovirulence factors has not been exhaustively studied.
In a recent comprehensive genomic analysis of 43 UPEC isolates, we found that “core” genes,
defined as genes shared between all E. coli, constituted approximately 60% of each strain’s
genome. Further, we were unable to find any single set of genes that accurately delineated UPEC
from non-UPEC strains (Schreiber and Hultgren, personal communication). The lack of a strict
7

‘genetic’ definition of UPEC indicates that, in most cases, urovirulence in UPEC is more
complicated than carriage of a set of virulence-associated genes that are missing in non-UPEC
strains. Instead urovirulence in UPEC strains may be defined by alternative characteristics, like
propensity to certain patterns of gene expression, as is seen with niche specific expression of
type 1 pili in the bladder [54, 55], or the carriage of different alleles of core genes. There are a
number of different alleles of FimH, described later in this review, that alter the affinity of the
adhesin for its ligand and may be associated with more virulent strains. These alternative
characteristics may explain how genes that are highly conserved in both UPEC and non-UPEC
strains, like those that encode type 1 pili, contribute to pathogenesis during UTI.

The Host Response to Type 1 Piliated UPEC
The host has evolved several mechanisms to respond to type 1 pilus mediated binding in a
manner that favors bacterial clearance or killing. Caspase-dependent apoptosis and exfoliation of
superficial facet cells is observed within hours of type 1 pili binding and invasion in C57BL/6
mice [39,62,63]. This promotes the clearance of infected cells from the host during micturition
(Figure 1F). In the absence of cell exfoliation, the host can expel UPEC directly from an invaded
cell via a TLR-4 dependent mechanism, reducing the number of successful UPEC invasion
events and decreasing the overall number of IBCs formed during acute infection (Figure 1C)
[19]. UPEC interactions with the host also leads to the robust recruitment of immune cells,
mainly neutrophils and inflammatory monocytes, to the urinary tract as well as the up regulation
of pro-inflammatory cytokines which drive the mobilization of additional immune effectors [64–
68]. Several natural allele variants of FimH exist. The residues in the mannose-binding pocket of
FimH are invariant in all sequenced UPEC isolates [37,69], however there is diversity outside of
8

this pocket, including at a cluster of amino acids that are positively-selected in UPEC strains
[69]. Interestingly, mutations in these positively selected residues results in distinct FimH alleles
that are skewed into either elongated or compact conformations, which have been observed in
several X-ray crystal structures of FimH [25,26,70]. The elongated conformation corresponds to
the mannose binding conformation whereas the compact form binds mannose only weakly or not
at all [69,71,72]. When FimH is bound to the FimC chaperone, it adopts an elongated
conformation [26] however, upon its incorporation into the tip of the pilus, it can convert to a
compact conformation with an altered mannose-binding pocket [25,70]. In the FimCH complex,
all of the FimH allele variants tested have a high affinity for mannose. However, when
incorporated into a tip-like state, following a DSE reaction with the FimG adaptor, FimH
variants differ greatly in their mannose affinity suggesting that depending on the allele, FimH is
skewed toward either an elongated or compact form after its incorporation into the tip [73].
Interestingly, UPEC strains containing distinct FimH alleles also display altered levels of
pathogenicity during acute and chronic UTI in C57BL/6 [74] and C3H/HeN mice [73]. Of
particular interest we found that specific mutations in two positively selected residues, A27 and
V163, result in a FimH variant (FimH(A27V/V163A)) that resides within a tip-like complex
predominantly in a high-affinity mannose binding conformation [73]. Surprisingly, this FimH
allele is severely attenuated in a cystitis model [69,73]. These findings support the hypothesis
that FimH resides in an equilibrium of mannose-binding and non-binding conformations, which
are governed, in part, by the identity of select residues that are under positive selection in UPEC
isolates. The inter-conversion between high and low mannose-binding conformations is likely
important for tissue-binding and/or immune evasion, which may begin to explain why the
FimH(A27V/V163A) variant, which appears to be “locked” in a high-affinity elongated state is
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unable to cause infection in vivo despite its high-affinity for mannose. These findings may be
related to the important observation made by others that FimH conformation is influenced by
shear force leading to a “catch bond” model of FimH function [70–72,75,76]. Thus, the ability of
FimH to be incorporated into a pilus tip to interconvert into different conformations affects
virulence.

The Biophysics of FimH Structure and Function
Several natural allele variants of FimH exist. The residues in the mannose-binding pocket of
FimH are invariant in all sequenced UPEC isolates [37,69], however there is diversity outside of
this pocket, including at a cluster of amino acids that are positively-selected in UPEC strains
[69]. Interestingly, mutations in these positively selected residues results in distinct FimH alleles
that are skewed into either elongated or compact conformations, which have been observed in
several X-ray crystal structures of FimH [25,26,70]. The elongated conformation corresponds to
the mannose binding conformation whereas the compact form binds mannose only weakly or not
at all [69,71,72]. When FimH is bound to the FimC chaperone, it adopts an elongated
conformation [26] however, upon its incorporation into the tip of the pilus, it can convert to a
compact conformation with an altered mannose-binding pocket [25,70]. In the FimCH complex,
all of the FimH allele variants tested have a high affinity for mannose. However, when
incorporated into a tip-like state, following a DSE reaction with the FimG adaptor, FimH
variants differ greatly in their mannose affinity suggesting that depending on the allele, FimH is
skewed toward either an elongated or compact form after its incorporation into the tip [73].
Interestingly, UPEC strains containing distinct FimH alleles also display altered levels of
pathogenicity during acute and chronic UTI in C57BL/6 [74] and C3H/HeN mice [73]. Of
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particular interest we found that specific mutations in two positively selected residues, A27 and
V163, result in a FimH variant (FimH(A27V/V163A)) that resides within a tip-like complex
predominantly in a high-affinity mannose binding conformation [73]. Surprisingly, this FimH
allele is severely attenuated in a cystitis model [69,73]. These findings support the hypothesis
that FimH resides in an equilibrium of mannose-binding and non-binding conformations, which
are governed, in part, by the identity of select residues that are under positive selection in UPEC
isolates. The inter-conversion between high and low mannose-binding conformations is likely
important for tissue-binding and/or immune evasion, which may begin to explain why the
FimH(A27V/V163A) variant, which appears to be “locked” in a high-affinity elongated state is
unable to cause infection in vivo despite its high-affinity for mannose. These findings may be
related to the important observation made by others that FimH conformation is influenced by
shear force leading to a “catch bond” model of FimH function [70–72,75,76]. Thus, the ability of
FimH to be incorporated into a pilus tip to interconvert into different conformations affects
virulence.

The Role of P Pili in Pyelonephritis
The ability of UPEC to ascend from the bladder to the upper urinary tract likely involves
many genetic and environmental factors, one of which is thought to be the up-regulation of P pili
and corresponding down-regulation of type 1 pili [77]. P pili, which are encoded by the pap
operon, mediate adhesion of UPEC to kidney tissue resulting in pyelonephritis [61,78–80]. This
binding is dependent on the expression of the P pilus tip adhesin, PapG [56,81]. Three alleles of
PapG exist (PapG-I, -II, and -III) and each allele shows a distinct affinity for a series of Galα14Gal containing glycolipid receptors, which are expressed to various degrees in the kidneys and
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ureters of mammals [82]. Human kidneys, for example, abundantly express the ligands for PapGII, globoside, and thus are colonized with UPEC that express PapG-II alleles. Conversely, PapGIII binds strongly to Forssman glycolipid, which is present in dog but not in human kidneys.
Thus, different alleles of PapG mediate host tropisms [83–85].

Identifying Roles for Additional CUP Pilus Types during Disease
A recent analysis of 35 Escherichia spp. genomes and 132 plasmids identified a total of 458
CUP pili operons, representing 38 distinct CUP pilus types based on usher phylogeny [86,87].
CUP pili tipped with specific adhesins provides E. coli the ability to bind to distinct ligands with
stereo-chemical specificity. Single UPEC strains were found to carry as many as 16 distinct,
intact CUP pilus systems that likely aid UPEC strains in their colonization of many host niches,
including the gut, vagina, urethra, bladder, and kidneys. Thus, it is likely that the retention of
many distinct CUP pilus types reflects the adaptation to broad environmental and host niches and
their function in facilitating the various tropisms of E. coli [88]. Aside from type 1 and P pili,
UPEC strains encode a number of additional CUP pilus types for which a role in UPEC
pathogenesis is minimally defined or completely undetermined. S pili are known to bind
sialosyloligosaccaride residues in host cells and likely mediate infection of the ureters and
kidneys [89]. Clinical isolates containing S pili are often associated with more severe outcomes
in patients with UTI, including: pyelonephritis, sepsis, and meningitis. The Dr pili adhesin has
been shown to bind type IV collagen and decay-accelerating factor (DAF), both of which are
expressed in human kidneys. Dr pili enable UPEC colonization of the mouse renal interstitial
basement membrane [90,91]. The roles for CUP pili, including F1C, F9, Ygi, Yad, and Auf, have
been briefly explored and have been recently reviewed [92–94]. Identifying roles for additional
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CUP pilus types will enhance our overall knowledge of UTI pathogenesis and may provide novel
drug targets to treat patients with UTI.

Outcomes of UTI: Connecting Findings in Humans and Mice
Much of our understanding of UTI and rUTI pathogenesis comes from studies in mice. The
development of murine models of acute and recurrent cystitis have allowed for many important
advances in our understanding of UTI pathogenesis. However, it is also worth noting that the
UTI mouse models, like all animal models, have limitations. Behavior, genetic, and environment
differences between mice and humans make it challenging to translate all murine findings to
humans [99]. Here we discuss advances in our understanding of UTI pathogenesis based on
experiments performed in relevant mouse models and highlight how these findings have been
recapitulated in clinical studies performed in women with UTI or rUTI.
For women with UTI, several disease outcomes are possible, including: asymptomatic
bacteruria (ABU), acute self-limiting infection, or chronic/recurrent UTI [5]. Placebo studies in
women have shown that approximately 50% of UTIs do not resolve in the absence of effective
antibiotic treatment, implying that cystitis is not always self-limiting. These findings highlight
the importance of clinical intervention to resolve UTI and the developing crisis of emerging
multi-drug resistant uropathogens [95,96]. In naïve mice, there are two major outcomes of UTI:
(i) self-limiting acute infection that resolves within days of the initiation of infection with or
without the formation of quiescent intracellular reservoirs (QIR); or (ii) persistent, high-titer
bacteruria concomitant with high bladder bacterial burden and severe bladder inflammation
which, in the absence of antibiotic intervention, can last for the lifetime of the animal and is
referred to as chronic cystitis [100] (Figure 1H). The resolution of infection in mice is often
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accompanied by QIR formation [97] (Figure 1I). The exfoliation response results in the exposure
of the underlying transitional cells, which allows the subsequent invasion of UPEC into these
cells. However, unlike superficial facet cells, the underlying transitional cells do not support IBC
formation; instead UPEC establish QIRs, which are comprised of 8–12 dormant bacteria in
Lamp1+ vesicles [97]. The mechanism of QIR formation is unknown, however, these reservoirs
are able to reactivate and release UPEC back into the bladder lumen to initiate a new infection
cycle [97,98]. Interestingly, the fate of disease in mice is determined by whether an acute hostpathogen checkpoint, which is influenced by the genetic background of the mice, is triggered.
C57BL/6 mice are resistant to chronic cystitis after a single infection; however, they can develop
persistent bacteriuria and chronic cystitis when “superinfected”, by multiple transurethral
inoculations within a 24 hour period [74]. Elevated levels of interleukin-6 (IL-6), keratinocyte
cytokine (KC/CXCL1), and granulocyte colony-stimulating factor (G-CSF) in the serum of
C57BL/6 mice prior to the second infection predicted the development of chronic cystitis [74].
These same cytokines have been found to precede chronic cystitis in singly infected C3H/HeN
mice, which are prone to the development of chronic cystitis [100]. Superinfection of C3H/HeN
mice within a six-hour period doubles the proportion of mice that developed chronic cystitis.
Intracellular bacterial replication, regulated hemolysin (HlyA) expression, and caspase 1/11
activation were essential for this increase [74]. The chronic bladder inflammation that
accompanies chronic cystitis includes lymphonodular hyperplasia in the bladder submucosa and
urothelial hyperplasia that results in the loss of superficial facet cells. Similar histological
findings have been observed in humans suffering from persistent bacteriuria and rUTI [101,102].
Proteomic analysis of chronically infected bladders indicates that chronic inflammation also
results in bladder epithelial remodeling, which may help to explain why mice that experience
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chronic cystitis are more susceptible to rUTI upon further bacterial challenge weeks after
antibiotic intervention and resolution of the initial infection [67]. Studies of mice with rUTI may
also begin to explain why a history of UTI is a major risk factor for rUTI in women, highlighting
the clinical relevance of this mouse model. Elevated soluble serum biomarkers that were
predictive of rUTI were also detected in young women with UTI [67]. Interestingly, temperance
of the neutrophil response during the first 24 hours of infection, by inhibition of cyclooxygenase2 (COX 2), protected mice from chronic and recurrent cystitis [67]. These findings may help to
explain the outcome of a small clinical trial that compared the outcomes of women with UPEC
UTI after being given a three-day course of either ciprofloxacin or ibuprofen. The study found no
difference in UTI outcome between these two groups at four or seven days post treatment [103].
Another study found that symptomatically treating women suffering from uncomplicated UTI
with ibuprofen (without any antibiotics) resolved infection in two-thirds of the study group
[104]. These results indicate that ibuprofen, which works by inhibiting COX 1 and 2, may act to
decrease the severity of UTI in these patients. However, the second study also found that women
in the ibuprofen treated group suffered from more UTI symptoms (abdominal pain, increased
frequency of urination, dysuria) and were more likely to develop pyelonephritis [104].
The development of rUTI is likely a balance between bacterial factors and host genetics.
Murine studies have indicated that the innate immune response is critical for combating UTI,
which had been recapitulated in human clinical studies [105]. Therefore, mutations in the genes
involved in this early immune response can greatly influence the susceptibility of a host to UTI.
For example, certain polymorphisms and altered expression levels of innate immune genes, like
Toll-like receptor 4 (TLR4) and CXCR1, have been associated with less severe symptomatic
UTI but an increase in the development of ABU in women [105]. Alterations in the sequence or
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expression of other innate immune genes, like IRF3 and CXCR1, have been associated with
increased incidences of acute pyelonephritis [105].

Pili are Critical for the Establishment of UPEC and Enterococcus Mediated CAUTI
The introduction of a catheter into the urinary tract provides an additional surface on which
bacteria can adhere and establish infection. Uropathogens that are commonly associated with
CAUTI, like those belonging to the Enterococcus genus, also encode a number of distinct
adhesive factors and pili that permit attachment within the host. Of these factors, the
endocarditis- and biofilm-associated (Ebp) pilus has recently been identified to play an essential
role in the establishment and persistence of UTI in a catheterized mouse model [106–110]. Upon
catheterization, implanted catheters are coated with host-derived fibrinogen and are subsequently
bound by Ebp expressing Enterococcus faecalis (E. faecalis), a common enterococcal
uropathogen [109]. The Ebp pilus binds fibrinogen via its tip adhesin, EbpA, which contains an
N-terminal fibrinogen-binding domain [109]. The mechanism(s) by which fibrinogen enters the
bladder is still under investigation but is likely due to bladder damage that occurs during the
catheterization process and subsequent infection. Mechanical stress induced by insertion of the
catheter into the bladder results in the induction of a robust inflammatory response and severe
bladder edema in humans and mice [107,111–113]. Bladder inflammation, including increases in
serum cytokines IL-1α and IL-6, and edema, is elevated further upon introduction of E. faecalis
into the catheterized mouse [107]. Increases in IL-1α and IL-6 have been previously shown to
stimulate the release of fibrinogen from the liver into the bloodstream as a part of the proinflammatory response and circulating fibrinogen may then leak into the urinary tract via tissue
damaged during catheterization. Once in the bladder, fibrinogen is deposited on the catheter,
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providing a binding site for EbpA expressing E. faecalis. Catheterization and the subsequent
inflammatory response are essential in mediating CAUTI, as mice infected with E. faecalis in the
absence of a catheter are quickly cleared from the bladder [107]. Fibrinogen deposited onto the
catheter surface not only enhances E. faecalis biofilm formation but also promotes growth,
increasing the severity of the infection [109]. The ability to bind and utilize fibrinogen may be a
general feature of infection in gram-positive bacteria, (as has been shown for Staphylococcus
aureus (S. aureus), Staphylococcus epidermidis (S. epidermidis), and Group A streptococci) and
potentially in some fungal pathogens (as was recently shown for Candida albicans) [114,115].
The Ebp pilus also plays a role in the transition of E. faecalis infection from the bladder to the
kidneys. In E. faecalis, loss of the pilus reduces bacterial colonization of the kidneys and thus
lowers the incidence of pyelonephritis in infected mice [110].
UPEC, the leading cause of complicated UTI, can also use CUP pili to colonize the bladder
during catheterization [15,116]. However, unlike Enterococcal spp., UPEC does not rely on the
presence of the catheter to propagate high levels of bacterial colonization. In a CAUTI mouse
model, UPEC undergoes the same acute pathogenic lifecycle that is observed in cystitis models,
including: invasion into the tissue, IBC formation and maturation, the formation of filaments,
and the emergence of filamentous bacteria back into the bladder lumen [116]. However, in the
presence of the catheter, UPEC does appear to have a more robust extracellular population
during acute infection, which is likely due to UPEC colonization and subsequent biofilm
formation on the surface of the catheter [116]. Interestingly, type 1 pili are required for biofilm
formation and UPEC colonization of the catheter [116]. These studies continue to define the
importance of type 1 pili as a virulence factor during uncomplicated and complicated UTI in
mice.
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Development of Pili-Based Alternative Treatments to Treat or Prevent UTI and CAUTI
Pili are potential drug targets due to the critical roles they play in UTI and CAUTI
pathogenesis. Our understanding of the molecular mechanisms by which pili function and impact
disease has permitted the development of novel therapeutics, such as vaccines and small
molecule inhibitors, that target pili and block infection by preventing colonization. While a role
for pili during intestinal colonization by uropathogens is currently unstudied, identifying and
targeting pili that do permit intestinal colonization would provide a unique opportunity to target
the source of uropathogens that lead to downstream infections.

Vaccines
A number of promising vaccines that target a wide-range of UPEC virulence factors are
currently in development [117–121]. The FimCH vaccine, a subunit vaccine targeting the type 1
pilus adhesin FimH, is one such example. Significant protection was observed in subcutaneously
vaccinated mice and cynomolgus monkeys given an intra-muscular vaccination, with the
protected animals developing antigen-specific, long-lasting serum IgG antibodies [120,121].
Based on this data, it is presumed that the vaccine works by stimulating these FimH-specific IgG
antibodies that block UPEC colonization of the bladder. Consistent with this, the polyclonal
antibodies derived from vaccinated mice block FimH function and likely activate immune
effector cells, like phagocytes and complement, for clearance of the infection [120,121]. The
success of this vaccine in animal models highlights its potential as an alternative treatment to
UTI in humans. A FimCH vaccine adjuvanted with PHAD (Avanti Polar Lipids, Alabaster, AL)
is currently completing a Phase 1 human study. This study has enrolled about 67 women with
and without a history of rUTI (personal communication, Gary Eldridge).
18

Other CUP pilus types are the focus of additional vaccine candidates. One such candidate is
the PapDG subunit vaccine. P pili are strongly associated with pyelonephritis and as such have
been designed to target UPEC and prevent complicated upper UTIs [61]. Intraperitoneal
administration of the PapDG vaccine protects animals from infection and elicits a specific IgG
antibody response in cynomolgus monkeys [118,122]. The Dr fimbriae represents another
current vaccine target. Mice vaccinated with purified Dr fimbriae produce high titers of serum
antibodies against the fimbriae but do not have lower colonization rates in either the bladder or
kidneys [123].
Recent findings revealed an essential role for the Ebp pilus and its adhesin, EbpA, during E.
faecalis mediated CAUTI in mice. Interestingly, vaccinating mice with EbpA results in
significant protection against subsequent E. faecalis CAUTI compared to unvaccinated mice or
mice vaccinated with other Ebp pilus protein subunits [109). Vaccinating mice with only the Nterminal portion of EbpA, which contains the fibrinogen-binding domain, is also sufficient to
protect mice from subsequent infection and may provide a higher level of protection than
vaccination with the entire adhesin.

Small Molecular Inhibitors
The importance of the FimH-mannose interaction during infection in mice has prompted
studies that test the effects of oral treatment with D-mannose or mannose-analogs on UTI
outcome. Oral D-mannose treatment has been shown in studies to work as well as antibiotics to
prevent rUTI. One group found that women who received prophylaxis with D-mannose after an
initial UTI had similar rates of rUTI as a group that received antibiotic prophylaxis, indicating
that D-mannose may be useful to prevent rUTI [124]. Another strategy to prevent UPEC
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pathogenesis has been the design of orally active, synthetic, small-molecule inhibitors of CUP
pilus assembly or function. One such class of small molecule inhibitors are mannosides.
Mannosides are mannose analogs that were rationally designed to bind within the mannosebinding pocket of FimH with a high affinity and thus block pilus binding of FimH to host
receptors (Figure 2) [125,126]. Studies in mouse models have demonstrated that mannosides are
potent, fast acting and highly efficacious in the treatment of UTI and CAUTI [116,127–129],
highlighting their potential as a novel therapeutic strategy for UTI. Mannoside treatment is
especially promising as a novel antibiotic sparing therapeutic because they are effective against
multi-drug resistant uropathogens [128]. While D-mannose and mannosides both appear to
effectively block FimH-mannose interactions, mannosides have approximately a 1,000,000-fold
increase in potency for inhibiting FimH, making them promising antibiotic-sparing therapeutics
[125,130].
Another class of compounds are pilicides, which are small, rationally designed 2pyridinones that block pilus assembly (Figure 2) [131,132]. Pilicides block assembly by binding
to the pilus chaperone, preventing chaperone-pilus subunit-usher interactions that are
fundamental for pilus biogenesis [133]. While pilicides were originally designed to target type 1
pilus assembly, recent studies have found that pilicide treatment disrupts assembly of at least
four-CUP pilus types (type 1-, P-, S-, and Dr- pili) as well as flagellar motility [134,135]. The
ability of pilicides to target multiple pilus types makes it an extremely valuable treatment option.

Conclusions
Complicated and uncomplicated UTI are extremely common, affecting a large portion of the
global population. The high rate of infection and recurrence of UTIs, their monetary cost, their
physical burden, and the increasing occurrence of antibiotic resistant uropathogens emphasize
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the need for effective treatments to combat the common causative agents of UTI and CAUTI,
like UPEC and Enterococcus strains. Understanding the molecular mechanisms by which
uropathogens are able to cause disease is the first step to identifying novel drug targets. Adhesive
pili, like type 1, P, and Ebp, have been shown to play essential roles in UTI pathogenesis in
mouse models and provide potential drug targets that may greatly reduce or prevent infection in
patients. While the mouse models of uncomplicated UTI and CAUTI have been shown to mimic
disease in human patients, the success of vaccine and small molecular inhibitor therapies against
these pili in humans is dependent on determining the efficacy of these treatments in clinical
trials.
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Figures

Figure 1. Uropathogenic E. coli (UPEC) pathogenic cascade during cystitis. (A) UPEC
residing in the gut are shed in the feces and colonize the peri-urethral and vaginal areas
before ascending into the bladder. Upon accessing the bladder, UPEC adhere to the surface
of superficial facet cells that line the bladder lumen in a type 1 pili dependent manner (B).
Adherent bacteria invade into the facet cells and are either expelled back into the lumen by
the cell in a TLR-4 dependent manner [19] (C) or escape from the endocytic vesicle into the
cytoplasm (D). Upon invasion, bacteria replicate in the cytoplasm forming intracellular
bacterial communities (IBCs) (E). One host mechanism of defense against intracellular
UPEC is the shedding of urothelial cells into the urine (F), which reduces the overall
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number of UPEC in the bladder. During the late stages of IBC formation, filamentous
bacteria dissociate from the IBC, burst out of the cell and back into the bladder lumen where
they remain or can invade an adjacent facet cell (G). There are two potential outcomes of
infection: chronic cystitis or resolution of infection. Uncontrolled bacterial replication in the
urine occurs in mice that develop chronic cystitis (H). In mice that resolve infection, small
pockets of bacteria, termed quiescent intracellular reservoirs (QIRs), form and reside in the
underlying urothelium and may seed future rUTI (I).
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Figure 2. Mannosides and Pilicides prevent uropathogenic E. coli (UPEC) urinary tract
infections (UTI) by targeting the function or formation of type 1 pili. (A,G) Unfolded
pilus subunits are secreted to the periplasm by the Sec apparatus. (B,H) Upon entering the
periplasm, unfolded subunits immediately interact with the cognate chaperone (FimC).
Subunits have an incomplete Ig-like fold which must be completed in order to properly fold.
In a process called donor strand complementation (DSC) FimC donates its G1 β-stand to the
subunit, stabilizing it (C,I). Subunits that do not interact with FimC are unable to fold
correctly and are degraded (D). The chaperone then delivers the subunit to the outer member
usher, FimD (E). Upon reaching FimD the subunit is assembled into the maturing pilus via
donor stand exchange (DSE) with the adjacent pilus subunit (F). Mannosides prevent type 1
pilus function by binding, in an irreversible manner, to FimH and therefore prevent the
interaction of FimH and mannose on the bladder surface (G). Pilicide works by halting pilus
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assembly. These molecules enter the periplasm (J) and bind to the pilus chaperone, halting
assembly (K).
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Chapter 2: Type 1 and F17-like Pili Promote
UPEC Intestinal Colonization
Adapted from:
Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist
Caitlin N. Spaulding, Roger D. Klein, Ségolène Ruer, Andrew L. Kau, Henry L.
Schreiber IV, Zachary T. Cusumano, Karen W. Dodson, Jerome S. Pinkner, Daved H.
Fremont, James W. Janetka, Han Remaut, Jeffrey I. Gordon, Scott J. Hultgren
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Abstract
Uropathogenic E. coli (UPEC) are responsible for 80% of community-acquired and 65%
of nosocomial urinary tract infections (UTI)1,2, which together affect 150 million people
annually3. Despite effective antibiotic therapy, 30-50% of patients experience recurrent UTI
(rUTI)3. In addition, the growing prevalence of UPEC strains resistant to last-line antibiotic
treatments like fluoroquinolones, and more recently carbapenems and colistin, make UTIs a
prime example of the current antibiotic-resistance crisis and emphasize the dire need to develop
new approaches for treatment and prevention of bacterial infections4,5. It is widely accepted that
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UPEC: i) establish reservoirs in the gut; ii) are shed in the feces; iii) are then able to colonize the
peri-urethral area or vagina and subsequently ascend through the urethra to the bladder and/or
kidneys, where they cause cystitis and/or pyelonephritis, respectively6. Chaperone-usher pathway
(CUP) pili such as the mannose-binding type 1 pilus mediate colonization of the bladder, but
little is known regarding the mechanisms underlying UPEC persistence in the intestinal tract.
Single UPEC isolates can encode up to 16 distinct CUP pilus operons and each pilus type is
thought to enable colonization of a microhabitat within a host or the environment7. In the present
study, we use a mouse model to examine the ability of a human UPEC strain harboring nine
different CUP operon mutants to colonize the gut. We found that both F17-like and type 1 pili
promote intestinal colonization and show distinct binding to epithelial cells distributed along
colonic crypts. Phylogenomic and structural analyses reveal that F17-like pili are closely related
to pilus types carried by intestinal pathogens, but are restricted to extra-intestinal pathogenic E.
coli (ExPEC), and have a distinct ligand specificity.

Main Text
Type 1 and F17-like pili promote UPEC intestinal colonization
To examine the role of CUP pili in colonization of the gut by human UPEC strains, we
developed a streptomycin mouse model of UPEC intestinal colonization8. We pretreated 6-week
old female C3H/HeN and C57BL/6 mice with an oral dose of streptomycin, followed 1 day (d)
later by an oral gavage (108 CFU) of a well-characterized human cystitis UPEC strain (UTI89)
containing engineered chromosomal kanamycin or chloramphenicol antibiotic resistance
markers. Sampling of feces collected 1-21 d following oral inoculation, plus surveys along the
length of the gut conducted at the time of sacrifice, revealed that stable colonization was
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achieved in both mouse backgrounds when they had been pretreated with streptomycin, in
contrast to controls that did not receive antibiotic (Figure 3).
The UTI89 genome contains 11 distinct CUP operons, 9 of which include all of the genes
necessary to assemble a full, functional pilus. To determine if any of the 9 intact CUP operons
promote intestinal colonization, C3H/HeN mice were co-colonized with wildtype (WT) UTI89
and one of 9 different mutant strains, each lacking a single CUP operon. Individual deletion of 7
CUP pilus operons yfc, yeh, yad, pap, sfa, yqi, and mat had no effect on the fitness of UTI89 in
the gut compared to the isogenic WT strain (Figure 4a-g). However, deletion of the fim or ucl
pilus operons, which encode type 1 and F17-like pili, respectively, resulted in significant
colonization defects (up to 100- and 1000-fold, respectively; Figure 4h,i). Deletion of the gene
encoding the type 1 pilus adhesin, fimH, mirrored the intestinal defect caused by deletion of the
full type 1 pilus operon (Figure 5a). Deletion of both pilus types in a single strain produced a
fitness defect greater than either individual deletion alone, suggesting that these two pilus types
do not have redundant roles (Figure 4j,k).

F17-like pili do not contribute to UTI in a mouse model of UTI
In a mouse model, type 1-mediated binding to mannose is indispensible for bladder
colonization and for invasion of the urothelial cells that line the bladder on its luminal side1,2.
Once inside urothelial cells, a single bacterium can rapidly divide to form an intracellular
bacterial community (IBC) containing 104-105 organisms1,2. Additionally, in mice that
spontaneously resolve bacteriuria, small collections of bacteria can remain in quiescent
intracellular reservoirs (QIRs) located within transitional bladder cells underlying the
urothelium1,2. Bacteria from QIRs can serve to seed rUTI1,2. Numerous studies have shown
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that mutations in fimH abolish the ability of UPEC to colonize the bladder, form IBCs and
QIRs1,2,9. In contrast, we found no role for the F17-like pilus in bladder colonization (Figure
6). Both the WT and UTI89Δucl strains (i) produced similar numbers of IBCs 6 hours post
infection (Figure 6e), (ii) had similar CFUs 28 days post infection in the urine, bladder, and
kidneys (Figure 6b,d) and (iii) were capable of maintaining bladder-associated CFUs after
resolution of bacteriuria, suggesting that UTI89 and UTI89Δucl are similarly capable of forming
QIRs (Figure 6c,d). Paradoxically, one study found that genetically engineered E. coli strains
overexpressing the ucl operon in vitro bind to desquamated epithelial cells harvested from
human urine10. It is possible that this paradox is explained by differences between mouse and
human bladders or that over-expression of F17-like pili in vitro may promote binding to cells
from a habitat where the F17-like pilus is not normally expressed in vivo. Thus, in contrast to the
significant reduction in intestinal colonization seen for both type 1 and F17-like mutants, no role
was observed for the F17-like pilus in the rate or severity of bladder infection in individual or
concurrent transurethral inoculations of UTI89 and isogenic UTI89Δucl strains into the bladders
of C3H/HeN mice.

Type 1 and F17-like pili bind to distinct micro-habitats in the mouse colon
Type 1 and F17-like operons each encode a two-domain tip adhesin, FimH and UclD,
respectively. The N-terminal lectin domain of the adhesin is responsible for recognition and
attachment to specific ligands, while the C-terminal pilin domain connects the adhesin to the
bulk of the pilus2. We cloned and purified the lectin domains of FimH and UclD and tested their
ability to bind to sections of mouse colon. Purified FimH lectin domain (FimHLD) bound to more
differentiated epithelial cells located in the upper portion of crypts and in ‘surface epithelial
47

cuffs’ (the colonic homologs of small intestinal villi) (Fig. 4l). FimH binding was prevented by
pretreatment of the tissue sections with PNGase, which cleaves N-linked oligosaccharides. This
is consistent with known FimH specificity for mannosylated ligands since mannose is a major
constituent of N-linked oligosaccharides (Fig 4l). FimHLD also bound to Caco-2 cells (an
immortalized human enterocyte-like cell line derived from colorectal carcinoma) and binding
was inhibited by both D-mannose and a high affinity mannose-analog (mannoside), M428411
(Figure 5b). The UclD lectin domain, UclDLD, also bound to colonic epithelial cells in tissue
sections. Binding was inhibited by pretreatment of the tissue sections with O-glycosidase, an
enzyme that cleaves O-linked oligosaccharides, suggesting that the UclD ligand is contained
within an O-glycan (Fig. 4m). Interestingly, FimHLD and UclDLD appeared to bind at distinct
locations within the mouse colon; while FimHLD bound to the upper region of the crypts, UclDLD
binding was restricted to the lower portion of crypts, suggesting that these pilus types promote
colonization of specific niches due to binding of different carbohydrate structures expressed by
epithelial cells at different stages of their differentiation (Fig 4l-m).

F17-like pili are closely related to pilus types used for intestinal colonization and
pathogenesis
CUP pili are highly conserved throughout Proteobacteria and are assembled by dedicated
chaperone-usher assembly machines encoded by each respective CUP operon along with the
various subunit types comprising the pilus fiber2,7. The sequence identity between usher genes of
distinct CUP pilus types is greater than the identity of genes that encode other CUP pilus proteins
and thus can be compared to elucidate the evolutionary relationship of CUP pili amongst all
proteobacterial strains7,12. Using this type of usher analysis, six large clades of pili have been
48

described. The γ clade, which is the largest, has been divided into subclades, including the γ1
subclade containing the fim operon of E. coli, Klebsiella, and Salmonella and the γ4 clade
containing the ucl operon7,12. To examine the evolutionary origin of F17-like pili, we performed
a homology search of a database of γ-Proteobacterial genomes and found that the UTI89 F17like usher gene sequence (uclC) shared highest identity with other E. coli uclC sequences and
with orthologous usher sequences of P. mirabilis, a bacterium that can colonize the gut, and S.
enterica, an intestinal pathogen (Table 1). The uclC usher gene was also closely related to the
gene encoding the F17 pilus usher (thus the derivation of the name, F17-like), as well as two
ushers for uncharacterized pilus types, pVir99 and ECs1278 (Table 1). A phylogenetic analysis
showed clustering of these E. coli and Proteus species’ ushers into a distinct sub-branch within
the broader F17 group usher phylogeny, suggesting that they share a common ancestor (Figure
7). E. coli are categorized into six distinct groups or clades of genetically related strains (clades
A-E)10,13. F17-like pili are encoded by genes present in only 10% of all E. coli strains; these
strains are almost exclusively in the B2 clade that harbors the majority of extraintestinal
pathogenic E. coli (ExPEC)10. In contrast, F17 and ECs1278 pilus operons are found in the
intestinal pathogens, enterotoxigenic E. coli (ETEC) and enterohemorrhagic E. coli (EHEC),
respectively, which are specific to clades E, B1, and occasionally A14,15. These findings suggest
that UPEC strains in clade B2 may have acquired the ucl operon from a different species and
retained this factor to facilitate its residency in the gut. A number of genetic variants of the E.
coli F17 adhesin, F17G, have evolved that bind different ligand variants, all containing a core Nacetylglucosamine (GlcNAc) moiety16. No binding of UclDLD was observed to GlcNAc, either
with the Center for Functional Glycomics glycan array or via differential scanning fluorimetry,
indicating that the F17-like pilus binds a ligand distinct from that of the F17 pilus (Fig. 4n).
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Interestingly, although the amino acid sequence of the full length UclD adhesin has diverged
from that of the F17 adhesin F17G, it is virtually invariant across all strains encoding it (>99%),
suggesting that there is a single, distinct ligand for UclD adhesins10.

Structural analysis of the F17-like adhesin, UclD
To examine the distribution of F17-like pili specifically in UTI isolates, a comparative
genomic analysis was performed on 43 strains isolated from a cohort of 14 women at the time of
initial presentation with acute UTI, or during subsequent recurrent UTIs17. Fourteen of the rUTI
events were caused by B2 strains, which encompass the majority of E. coli strains that cause
UTI10,13. Of these 14 strains, 13 encoded F17-like pili (~93%) (Figure 8). In contrast, F17-like
pili have been found in less than 50% of all B2 strains10 (E. coli reference collection (ECOR)).
We concluded that F17-like pili are enriched in B2 isolates associated with rUTI episodes in
women from this cohort. This data, along with our findings that F17-like pili promote UPEC
intestinal colonization, suggest that F17-like pili might be associated with UPEC persistence in
women with rUTI due to their ability to promote maintenance of a UPEC intestinal reservoir.
To better understand the role of the F17-like pilus in gut colonization, we solved two high
resolution X-ray crystal structures of UclDLD. Overlay of the structures in the P21 (green) and
P212121 (gray) space groups resolved to 1.05 Å and 1.6 Å, respectively (Table S2) reveals they
are nearly identical (Figure 9a-1). These structures show that nine β-strands within UclDLD
coalesce to form an elongated β-barrel structure. Seven additional β-strands, one α-helix and two
short 3/10 helices, that are located within inter-strand loops, comprise the remainder of the
protein (Figure 9a-1). Comparison of the P21 UclDLD structure with the previously solved lectin
domain structure of an F17 adhesin, F17GLD (Figure 9a-2), (PDB 1OIO18) indicates that, despite
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a sequence identity of only 25%, the overall secondary structure characteristics are remarkably
conserved between these two pilus types as seen when the structures are overlayed (Figure 9a3). Nevertheless, a structural alignment of the two lectin domains reveals two large insertions in
UclD relative to the F17G sequence (Figure 9b; highlighted in orange and yellow). The first
insertion is an elongation of the loop located between strands 4 and 5 and is highlighted in
orange in Figure 9b,c. The second insertion is located between strands 8 and 9 (highlighted in
yellow in Figure 9b,c), and contains a short 3/10 helix. Previous studies have demonstrated that
the GlcNAc receptor binding site for the F17G adhesin is located on the side of the lectin domain
(Figure 9a,d)16. Comparison of the UclDLD and F17GLD structures suggests the presence of a
transverse binding site along the surface of UclDLD located in a similar position to the GlcNAc
binding site on F17G (Figure 9a,d). This binding site, highlighted in purple in Figure 9c and by
purple residues and stars in Figure 9b is directly adjacent to the helix-containing insertion
located between strands 8 and 9 (colored yellow in Figure 9b,c), and located slightly above the
elongated loop between strands 4 and 5 (colored orange in Figure 9b,c). The proximity of the
putative binding pocket to both insertions suggests that these regions may be involved in creating
UclD’s unique receptor binding specificity.
The proposed UclD binding pocket is comprised of residues found in the loops
connecting strands 6 and 7, strands 8 and 9, and within strands 2b and 9. Six key residues (Q43,
W103, D119, N131, T134, and S136) within this pocket are denoted with stars in Figure 9b and
shown as sticks in Figure 9d). The corresponding residues in the F17G binding site are
chemically distinct from their UclD counterparts, (Figure 9b,d) providing further evidence to
support our observation that UclD does not share a molecular ligand with F17G.
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Comparison of residue positioning and electrostatic surface potential of the putative
binding site between both UclDLD structures suggests that W103 may play a key role in the
coordination of a sugar residue within the binding pocket, as tryptophan residues have an
established role in aromatic-sugar stacking interactions in bacterial carbohydrate binding
proteins19. In the P21 space group, W103 is positioned adjacent to a putative binding pocket that
is 11 Å wide and 7 Å deep. In contrast, the P212121 structure shows well-resolved density
indicating that the W103 side chain is flipped approximately 120 degrees, partially occluding the
proposed binding pocket (Figure 9d). These differences may arise from differences in crystal
packing, but may also indicate flexibility in the W103 residue that may play a regulatory role in
ligand binding.

Conclusions
Identifying the role of novel UPEC virulence factors, like type 1 and F17-like pili in gut
colonization, revealed new mechanisms of UPEC association with its host. Specifically,
identification of the role of F17-like pili in intestinal colonization and its relatedness to
homologs in other bacteria that inhabit the gut provides new insights into a previously
uncharacterized CUP pilus type. Further examination of the ligands and micro-evolution of this
pilus type is needed to dissect the specifics of its role in gut colonization. In addition,
identification of genes involved in UPEC colonization of the gut may also provide a method by
which UTI patients could be stratified for epidemiologic studies of disease recurrence risk as
well as for proof of concept clinical studies of the efficacy of CUP-directed treatment regimens.
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Materials and Methods
Ethics statement
The Washington University Animal Studies Committee approved all procedures used for the
mouse experiments described in the present study. Overall care of the animals was consistent
with The Guide for the Care and Use of Laboratory Animals from the National Research Council
and the USDA Animal Care Resource Guide. For collection of colonic tissues for adhesion
binding studies, mice were sacrificed according to institutional, national and European animal
regulations, using protocols that were also approved by the animal ethics committee of Ghent
University.

Bacterial strains
CUP operon and adhesin deletions in UTI89 were engineered by replacing the gene(s) of interest
with antibiotic-resistance markers using the λ Red Recombinase system20. Earlier reports
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described WT UTI89 and its isogenic fim and fimH mutants21,22 as well as EC95823, 41.4p24 and
CFT07325.

Colonization of mice with UPEC strains
6-week old female C3H/HeN mice were obtained from Envigo or Charles Rivers Labs (CRL). 6week old female C57BL/6 mice were also obtained from Envigo. Animals were maintained in a
single room in our vivarium for no more than 2 days prior to treatment. Prior to and after
treatment all animals received PicoLab Rodent Diet 20 (Purina) ad libitum. All animals were
maintained under a strict light cycle (lights on at 0600h, off at 1800h). For competitive
infections, if a phenotype was observed after testing five mice (1 biological replicate), the
experiment was repeated 1-2 times (total of n=10-16 mice, 2-3 biological replicates). For 16S
rRNA analyses, 4-5 mice were examined (1 biological replicate). For all other experiments, 9-16
mice were tested and the experiment was repeated 2-3 times (2-3 biological replicates).
Exclusion criteria for mice were pre-established; (i) both introduced strains in competitive
infections became undetectable during the course of a 14 day experiment, and (ii) mice died or
lost > 20% of their body weight. No mice in this study met these criteria. Mice were acquired
from indicated vendors and randomly placed into cages (n=5 mice/cage) by employees of
Washington University’s Division of Comparative Medicine (DCM); no additional methods for
randomization were used to determine how animals were allocated to experimental groups.
Investigators were not blinded to group allocation during experiments.
Animals received a single dose of streptomycin (1000mg/kg in 100 µL water by oral
gavage (PO)) followed 24 h later by an oral gavage of ∼108 CFU UPEC in 100 µl phosphatebuffered saline (PBS). Bladder infections were performed via transurethral inoculation26. UPEC
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strains were prepared for inoculation as described previously26. Briefly, a single UTI89 colony
was inoculated in 20 mL of Luria Broth (LB) and incubated at 37°C under static conditions for
24 h. Bacteria were then diluted (1:1000) into fresh LB and incubated at 37°C under static
conditions for 18-24 h. Bacteria were subsequently washed three times with PBS and then
concentrated to ~1x108 CFU per 100 µL for intestinal infections and ~1x108 CFU per 50 µL for
bladder infections.
In all cases, fecal and urine samples were collected directly from each animal at the
indicated time points. Fecal samples were immediately weighed and homogenized in 1 mL PBS.
Urine samples were immediately diluted 1:10 prior to plating. Mice were sacrificed via cervical
dislocation under isofluorane anesthesia and their organs were removed and processed under
aseptic conditions. Intestinal segments (cecum and colon) were weighed prior to homogenization
and plating on LB supplemented with the appropriate antibiotic.

Enumeration of bladder intracellular bacterial communities (IBCs)
6 week old C3H/HeN mice were given a single oral dose of either M4284 (100mg/kg) or vehicle
control (10% cyclodextrin) 30 min before transurethral inoculation with UTI89. To accurately
count the number of IBCs, mice were sacrificed 6 hours after infection. Bladders were removed
aseptically, bi-sected, splayed on silicone plates and fixed in 4% (v/v) paraformaldehyde. IBCs,
readily discernable as punctate violet spots, were quantified by LacZ staining of bladder
wholemounts27,28.

Immunofluorescence Studies
The protocols used for immunohistochemical analysis are based on a previous study29.
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Following sacrifice of 6 week old, female C57BL/6 mice (supplied by VIB-Ghent University
breeding program, Belgium), segments of colon were fixed in methanol-Carnoy for a minimum
of 3 hours at room temperature. The fixed tissues were then embedded in paraffin and 4-µmthick sections were cut and placed on glass slides. Slides were de-paraffinized and re-hydrated
by incubating them in xylene, isopropanol, 100% ethanol and finally 70% ethanol (each step
involving a 3 min incubation in the reagent followed by another 3 min incubation in fresh
reagent). Slides were subsequently rinsed in tap water and PBS, placed in blocking buffer (5%
fecal calf serum prepared in PBS) at room temperature for 30 min, and then incubated with
rabbit polyclonal antibodies to Muc2 [1/2000; Mucin 2 (H-300), Santa Cruz Biotechnology] for
2 h. After three washes with PBS, slides were incubated with a goat anti-rabbit Dylight-488
labeled secondary antibody (1/1000 dilution, ThermoFisher Cat No. 35553) in blocking buffer
for 1 h at room temperature. Slides were washed three times with PBS before counterstaining
with bis-benzimide (Hoechst dye) (1/1000 in PBS) for 10 min at room temperature. Finally,
slides were incubated with FimHLD or UclDLD (P21) protein, labeled with NHS 650nm Dylight,
in blocking buffer at 4°C overnight. Prior to staining, sections were treated with O-glycosidase
(NEB) or PNGaseF (SIGMA) at 37°C using buffers and protocols supplied by manufacturer .
Slides were washed subsequently with PBS before treatment with fluoro mounting medium (npropyl gallate in glycerol) and viewing under a confocal microscope (Leica Microsystems LASAF-TCS SP5) using a 20x125 objective.

Carriage of F17-like pili
We examined 43 available UPEC isolates (Table 2). These isolates originated from a clinical
study of 14 women who experienced at least two episodes of UTI (an initial UTI and one or
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more rUTI) during the 90 day study window17. The isolates used in this work were sequenced in
a previous study24 (Bioproject ID: PRJNA269984) and include (i) 14 isolates collected at
enrollment, (ii) 18 isolates collected during rUTI (10 women experienced a single rUTI while
four women experienced two rUTI events), and (iii) 11 isolates collected in the days leading up
to an rUTI.
The distribution of the F17-like operon in these clinical E. coli isolates was determined
using BLAST and the F17-like operon from UTI89 as the query sequence. A “hit” was
considered as any genome sequence that matched the entire length of the query sequence with
>75% identity. As a control to prevent false negatives in the BLAST search of draft genomes,
DNA sequencing reads from each clinical UPEC isolate were mapped against a reference
sequence constructed by concatenating all the ucl genes with 100 N’s separators using Geneious
v6.1.730.

Phylogenetic Analyses and Sequence Alignments
Amino acid alignments of full-length UTI89 UclD, P. mirabilis UcaD, S. enterica UclH, and
ETEC F17G were conducted using the MAFFT L-INS-i iterative refinement method and the
default BLOSUM62 scoring matrix (Table 1)31. MAFFT collected up to 100 homologs with E
values of less than 1e-10 to each sequence from the SwissProt database to improve alignment
accuracy. Homologs are automatically removed from the final alignment. The alignment was
visualized using Geneious30. A homology search of the coding sequence database of the
European Nucleotide Archive (ENA) was conducted using the Basic Local Alignment Search
Tool (BLAST)32 using the UTI89 uclC (ENA accession: ABE10308) and EDL933 ECs1278
(ENA accession: AIG67653) as queries. Sequences that matched either gene sequence with
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>50% identity were downloaded and then filtered to remove partial hits (<80% length of query
sequence) and sequences with nonsense mutations, which resulted in a total of 659 sequences
(Supplementary table 1). Duplicate sequences were then removed, resulting in a list of 122
unique, representative sequences. These sequences were then aligned with the UTI89 fimD usher
sequence (ENA accession: ABE10417) as an outgroup using the MAFFT MAFFT L-INS-i
alignment method and the 200PAM scoring matrix31: The phylogenetic relationship between
gene sequences was then estimated using RAxML v8.1.3 with the GTRCAT model and
supported with 1000 bootstrap replicates; the tree was visualized using the tool interactive Tree
of Life (iTOL) v333.

Enzyme-linked immunosorbent assay (ELISA) targeting FimH
Caco-2 cells (ATCC Number HTB-37) were cultured in minimum essential medium (MEM)
supplemented with 20% fetal bovine serum (FBS). Cell cultures tested negative for mycoplasma.
Cells were split into 48-well plates, grown to 100% confluence and then fixed with
paraformeldahyde for 15 min followed by treatment with blocking buffer (1x PBS containing 2%
BSA) for 2h. A truncated FimH, corresponding to residues 1-178 of the mature FimH adhesin
(FimHLD), expressed in E. coli and purified as described previously34, was serially diluted in
blocking buffer and incubated with the fixed CaCo-2 cells for 1h at room temperature. To test
the effect of D-mannose or M4284 on FimH binding, 0.2 mg/mL FimHLD was pre-incubated for
5 min in the presence or absence of 1 mM D-mannose (Sigma-Aldrich) or 1mM M4828 (in 20
mM Tris pH 8.0 or 20 mM Tris plus water or 10% cyclodextrin, respectively) before serial
dilution and incubation. Wells were washed four times with PBS/0.05% Tween 20 (PBST) prior
to incubation with a polyclonal rabbit anti-T3 antibody against FimHLD (generated against FimH
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residues 1-165; ref. 39) for one hour at room temperature. Following another series of four
washes, secondary antibody (goat anti-rabbit Ig conjugated to horse radish peroxidase;
ThermoFisher, Catalog Number 32460) was incubated with the cells for 1 h at room temperature
(24oC) before washing in PBST. Plates were developed with the BD OptEIA TMB substrate
reagent kit for 5 min at room temperature (24oC) before quenching with 1 M H2SO4. Binding
was assessed by measuring the absorbance at 450 nM on a TECAN infinite 2 PRO plate reader.
Wells lacking protein were used as control. All conditions were examined in quadruplicate.

F17-Like Constructs and Purification
For the P21 UclDLD construct, the first 197 amino acids of the mature UclD adhesin protein were
cloned into pDEST14 using Gateway® technology (Invitrogen), resulting in plasmid pUclDAD.
Expression was induced with 1mM IPTG. Periplasmic extracts were prepared by resuspending
bacterial pellets in 20mM Tris/20% sucrose (pH 8) (4 ml/per gram of pellet). Subsequently, 40µl
of 0.5M EDTA and 10mg/ml lysozyme were added per gram of pellet and the suspension was
incubated on ice for 30 min. This step was followed by addition of 40 µl of 2.5M MgCl2 per
gram of cell pellet and incubation on ice for 5 min. Cells were spun at 15,000 x g and the
supernatant was saved as the periplasmic extract. The extract containing the UclD lectin domain
was dialyzed against 20mM HEPES pH 7, passed over a SP FF cation exchange column (GE)
and bound material eluted with 20mM HEPES pH7/ 1M NaCl. Pooled fractions containing UclD
lectin domain were then applied to a Phenyl Hi Trap column (GE) after addition of 1M
ammonium sulfate. Elution was performed using 20mM HEPES pH 7.
To generate purified UclDLD for the P212121 space group, DNA from the UTI89 uclD
gene encoding the N-terminal 217 amino acids of the protein were cloned into pTRC99a with a
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C-terminal 6-His tag. This construct was expressed in the periplasm of E. coli DL41(DE3), a
methionine auxotroph strain suitable for expression of native or selenomethionine-labeled
protein. Periplasmic extracts were first dialyzed against PBS supplemented with 250 mM NaCl,
then bound to a Cobalt (Goldbio) column; bound proteins were eluted with PBS containing 250
mM NaCl, and 250 mM imidazole. Pooled fractions were dialyzed into 20 mM MES (pH 5.8),
bound to an HR16/10 Mono S cation exchange column (GE Healthcare), and eluted with 300
mM NaCl. Following cleavage of the periplasmic localization sequence, the mature form of
UclDLD-6xHis contained 203 amino acids.
Selenomethionine-labeled protein was purified using the same protocol, but all buffers
were supplemented with 2 mM β-mercaptoethanol and 1 mM EDTA to prevent oxidation.
EDTA was omitted from the periplasmic dialysis buffer to prevent chelation of immobilized
cobalt.

Crystallization and Structure Determination
For the P21 UclDLD structure solved in the P21 space group, UclDLD (15mg/ml) was crystallized
using sitting drop vapor diffusion against a solution containing 16% PEG 4000, 0.1M Tris HCl
pH 8.5, 0.2M magnesium chloride. UclD crystals were flash cooled to 100oK in a solution
containing 16% PEG 4000, 0.1M Tris HCl pH 8.5, 0.2M magnesium chloride and 30% glycerol.
Data were collected at beamline ID29 (ESRF, Grenoble, France) to 1.05 Å resolution. Data were
indexed and processed with XDS35, scaled and merged using SCALA in the CCP4 suite36. Data
and refinement statistics can be found in Table 3.
For the UclDLD structure solved in the P212121 space group, UclDLD (10 mg/ml 10 mM
MES 5.8) was crystallized by the hanging drop vapor diffusion method against a well solution
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containing 0.1 M potassium phosphate (monobasic), 0.2 M potassium iodide and 20% PEG
3350. One microliter of the protein solution was mixed with 1 µL well solution and incubated at
18 °C. Crystals were harvested and transferred to a solution containing 0.1 M KH2PO4, 0.2 M KI
and 20% PEG 3350 supplemented with 20% glycerol before being flash-frozen in a bath of
liquid N2. Data were collected at beamline 4.2.2 (ALS Berkeley) to 1.6 Å resolution. Data were
indexed and processed with XDS35, scaled and merged AIMLESS in the CCP4 suite36 and
phased with the Single anomalous dispersion (SAD) method using phenix.autosol, and refined
with phenix.refine37. Data and refinement statistics can be found in Table 3. RMSD values were
calculating using the DALI server38. Structural alignments were performed in Promal’s 3D using
the default settings. Secondary structure assignments for UclDLD were completed using DSSP.

Differential Scanning Fluorimetry
Purified UclDLD (1.4 mg/well) was incubated with 5x Sypro orange fluorescent dye in 20 mM
Tris (pH 8.0) with or without 10 mM monosaccharide in a total volume of 70 µL. Samples were
heated from 20 °C to 100 °C in 30-second/0.5 °C increments using a Bio-rad C1000
thermocycler with CFX96 RT-PCR attachment. The reported melting temperatures were
determined by the inflection point of the sigmoidal graph.

Data Availability
Sequences used to examine the carriage of F17-like pili in clinical rUTI isolates were previously
published24 and are deposited in the NCBI under the Bioproject ID: PRJNA269984.
Crystallography data have been deposited in the PDB under accession codes: 5NWP (P21) and
5VQ5 (P212121).
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Statistical Analysis
The statistical significance of differences between groups in experiments (excluding competitive
infections) was determined by a Mann Whitney U test. Competitive Index (CI) was defined as
(CFU output strain A/CFU output strain B)/(CFU input strain A/CFU input strain B). For
competitive infections, statistical significance was determined by a Wilcoxon Signed Ranked
test. Statistical analyses were performed using Graphpad Prism 7.
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Figures

Figure 3. Streptomycin treatment allows for persistent UTI89 colonization of the intestine
in female C3H/HeN and C57BL/6 mice. (a) Mice were pretreated with streptomycin and
subsequently colonized via oral gavage (PO) with UTI89, a prototypical human UPEC cystitis
isolate. (b-e) Colonization of UTI89 in C3H/HeN mice from Envigo (panels b,c) or C57BL/6
mice from Envigo (panels d,e) was assessed by quantifying colony forming units (CFU) in fecal
samples collected over the course of 21 days from mice who did not receive streptomycin (white
circles) or mice pretreated with the antibiotic (black circles). CFU analysis of levels of
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colonization in the cecum and colon were defined by analyzing tissue homogenates prepared 21
days post colonization. Symbols represent geometric means ± SD, *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001 (Mann Whitney U test). n=15 mice, 3 replicates (panels b-e).

Figure 4. Type 1 and F17-like pili promote UPEC intestinal colonization. (a-i) C3H/HeN
mice were treated with streptomycin and concurrently colonized with 1x108 CFU of Wildtype
(WT) UTI89 and one of 9 CUP operon knockout strains. (a-g) Deletion of 7 CUP operons had no
impact on the fitness of UTI89. (h,i) Loss of operons that encode type 1 and F17-like pili (fim
and ucl operons, respectively) decreased fitness compared to the WT strain. (j) Deletion of the
fim and ucl operons in a single strain produced a fitness defect greater than deletion of each pilus
alone. (k) Strains lacking either or both pilus operons also had fitness defects at 4 days post
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gavage when singly-colonized. (l,m) Purified adhesin lectin domains for the type 1 and F17-like
pilus (FimHLD and UclDLD, respectively) were tested for binding to mouse colonic sections.
Sections were stained with Hoechst (blue) and rabbit antibodies to Muc2, a prominent mucusassociated glycoprotein (green). Purified FimHLD binds to epithelial cells positioned in the upper
half of crypts and surface epithelial cuffs. FimHLD binding is lost by pre-treatment of sections
with PNGase (compare top and bottom images in panel l). UclDLD binds to epithelial cells
located in the lower half of crypts. Binding is inhibited by pretreatment of sections with Oglycosidase (compare top and bottom images in panel m). To the right of the overview images in
panels l and m, we show higher power views of individual crypts. Arrowheads point to examples
of sites of binding of the purified adhesins. (n) The absence of a shift in the melting temperature
of UclDLD in the presence of five monosaccharides tested using differential scanning
fluorimnetry suggests that none of these sugars bind UclDLD in solution. In contrast, FimHLD
binds monomannose with high affinity, resulting in a mean melting temperature shift of ~11°C.
Abbreviations. Ce= cecum, Col= colon. CI= competitive index. Bars represent mean values ±
SEM in panels a-j, n and geometric means ± SD in panel k. *p<0.05, **p<0.01, ***p<0.001 by
Wilcoxon Signed Ranked test (panels a-j) or Mann Whitney U test (panel k). n=5 mice, 1
replicate (panels a, d-g), n=6 mice, 1 replicate (panel c); n=9, 2 replicates (panel j); n= 10 mice, 2
replicates (panels b,h) n=15 mice, 3 replicates (panels i,k).
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Figure 5. The FimH adhesin is required for type 1 pilus-dependent colonization of the
mouse gut and for binding to human intestinal epithelial cells. (a) C3H/HeN mice from
Envigo were pretreated with streptomycin and colonized with 1x108 CFU of WT UTI89 and
UTI89ΔfimH. The WT strain is able to outcompete the strain lacking the FimH adhesin. (b) The
ability of purified FimH lectin domain (FimHLD) to bind to Caco-2 cells was assessed by FimHELISA. Pre-incubation of FimHLD with a 50-fold excess of D-mannose (5mM) or M4284 (5mM)
results in significant reductions in FimH binding to the Caco-2 cells while 10% cyclodextrin
(M4284 vehicle) alone had no significant effect. All data shown are normalized to wells that
were not exposed to the purified adhesin. Abbreviations CI= competitive index. Ce= cecum,
Col= colon. Bars represent mean values ± SEM, *p<0.05, **p<0.01, ***p<0.001 (Wilcoxon
Signed Ranked test) in panel a. Bars represent mean ± SEM, *p<0.05 (Mann Whitney U test) in
panel b. n=14 mice, 3 replicates (panel a); n=4 replicates/treatment (panel b).
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Figure 6. F17-like pili are not required for UTI in mice. C3H/HeN mice received a
transurethral inoculation of UTI89 (WT) and UTI89Δucl, concurrently (a, b), or individually (ce). (a) UTI89Δucl and WT strains persist at similar levels in the urine over 28 d in competitive
infections. (b) The two strains are also present at equal levels in the bladder and kidney at the
time of sacrifice 28 days post infection. (c) Single infection with the WT strain (black circles) or
the F17-like mutant strain (white circles) produces similar levels of bacteruria over 28 days. (d)
Single strain infection also produces similar levels of viable cells in homogenates of whole
bladder or kidneys harvested at the time of sacrifice (28dpi). There was no statistically
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significant difference in the number of mice that resolved bacteriuria while maintaining bladderassociated CFUs after transurethral infection with either WT or UTI89Δucl (highlighted in red in
panel d), suggesting that both of these strains are capable of forming similar numbers of QIRs.
(e) Mice infected transurethrally with WT or UTI89Δucl formed a similar number of intracellular
bacterial communities (IBCs) at 6 hours in the bladder, indicating that loss of the ucl operon does
not alter UTI89’s ability to form IBCs. CI= competitive index. Bars represent mean ± SEM
(panels a,b), geometric mean (panels c,d) or median (e). No significant difference was detected
between any samples by Wilcoxon Signed Ranked test (panels a,b) or Mann Whitney U test
(panels c-e). n=10 mice, 2 replicates (panels a-b, e). n=16 mice, 3 replicates (panels c-d).
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Figure 7. Distribution of F17 usher homologs in Enterobacteriaceae. The phylogenetic
relationships between F17 homologs was estimated using the sequence of the usher genes.
Branch colors indicate host strain and pilus identity, while colored symbols indicate the
annotated pathotype of the E. coli strain for each sequence as determined by publically available
annotations. Stars indicate extraintestinal pathogenic E. coli (ExPEC) strains while circles
indicate intestinal pathogenic E. coli strains. Carriage of F17-like pili is enriched in UPEC strains
while F17 and ECs1278 pili are more common in intestinal pathogens such as EHEC. The strain
names for each sequence and ENA accession IDs are given. Numbers beneath the branches
indicate the percentage of support from 1000 bootstrap replicates (numbers greater than 80% are
shown).

75

76

Figure 8. Phylogenetic distribution of F17-like carriage in UPEC from patients with
rUTI. The phylogeny of a set of clinical UPEC strains (n=43 with taxon labels highlighted in
green, orange, or grey) was contextualized with reference E. coli strains (n=46, unhighlighted
taxon labels) by comparing the concatenated single-copy, core genes of the strains using the
RAxML algorithm and the GTRCAT model39. Highlighted taxon labels indicate UPEC isolates
collected at enrollment (green) and during recurrent UTI (orange). In all cases, patients cleared
each infection prior to recurrence, no patient exhibited signs of asymptomatic bacteriuria. The
study design also allowed for the collection, from cohort participants, of E. coli isolates present
in the urine in the days leading up to their clinical visit and rUTI diagnosis (highlighted in grey),
as described previously17. Branch lines indicate phylogenetic background for strains from clade
B2 (red branch lines) and non-B2 clades (blue branch lines). Carriage of F17-like pili (black
stars) was limited to the B2 clade and enriched within rUTI UPEC isolates. Bootstrap supports
are indicated at internal nodes. Bootstrap values >95 have been removed. The clade to which
each strain belongs is indicated in brackets to the right.
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Figure 9. Structural analysis of UclDLD. (a) Comparison of the structures of UclDLD and
F17GLD. Superposition of the P21 UclDLD (green) P212121 UclDLD (grey) crystal structures (a-1).
Crystal structure of the F17G adhesin (PDB 1OIO18) (a-2). Superposition of the P21
UclDLD (green) and F17GLD (cyan) crystal structures (a-3). Despite a primary sequence identity
of only 25%, the structures superimpose with an Cα root mean square deviation of of 2.7 Å. (b)
Structural alignment of the UclDLD and F17GLD amino acid sequences using the PROMALS3D
server. All 16 regions assigned as β-strands by the Dictionary of Secondary Structure of Proteins
(DSSP)40 are conserved in both proteins despite low sequence identities. UclD residues
highlighted in purple are postulated to contribute to binding of a small core ligand,
while surrounding residues highlighted in yellow and orange may bind to different moieties on a
larger molecular receptor. Starred residues are represented as sticks in panel d. (c) Surface
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representation of the UclDLD structure, with key regions of divergence highlighted in yellow,
orange, and purple according to the representation in panel b. (d) Comparison of residue
positioning and electrostatic surface potential of the putative binding site between the two
UclDLD structures and the known binding site of the F17GLD structure. We believe that the side
chain and/or backbone positions of Q43, W103, D119, N131, T134, and S136, shown here in the
stick representation, likely coordinate binding to a glycan-containing sugar residue in the
putative binding pocket. The residues occupying the analogous positions on F17G are also
shown as sticks.

79

Chapter 3: Selective depletion of uropathogenic
E. coli from the gut by a FimH antagonist
Adapted from:
Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist
Caitlin N. Spaulding, Roger D. Klein, Ségolène Ruer, Andrew L. Kau, Henry L.
Schreiber IV, Zachary T. Cusumano, Karen W. Dodson, Jerome S. Pinkner, Daved H.
Fremont, James W. Janetka, Han Remaut, Jeffrey I. Gordon, Scott J. Hultgren

Nature 2017 Jun 22; 546(7659) 528-532. doi: 10.1038/nature22972.
Copyright © 2017, Nature. All Rights Reserved.

Abstract
UTIs are a major contributor to global antibiotic use. In the United States alone, 9% of all
antibiotics prescribed in a year are for the treatment of UTIs 1. The global prevalence of single
and multi-drug resistant UPEC isolates highlights our reliance on antibiotics to treat these
infections and stresses the need to develop alternative treatments to combat resistant pathogens.
However, the development and spread of antibiotic resistance is not the only issue with our
current method of treatment. An increasing number of published papers are finding that
disruption of the gut microbiota by orally administered antibiotics, especially during childhood,
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may affect its functional properties in ways that are deleterious to the host, not only in the short
term but for more protracted periods of time if the antibiotic perturbation is not followed by
adequate restoration of the community 2,3. Therefore, developing treatments for pathogens, like
UPEC, that can specifically target a pathogen without damaging the remainder of the microbial
community is important. This ‘molecular-scalpel’ approach to drug development is increasing in
scope. Treatment with mannoside has recently been shown to target the intestinal population of
AIEC in a transgenic mouse model 4. The identification of a selective therapy that is designed to
target staphylococci spp. but has minimal other effects on the microbiota has shown that this type
of treatment is possible 5. Another study found that a cocktail of bacteriophages could target
UPEC in the gut with minimal impact on the overall composition of the microbiota; however, the
translatability of these types treatment to a wide-range of uropathogens and in hosts with
different genetics and microbial compositions is unknown 6.
My finding that type 1 pili promote UPEC intestinal colonization, outlined in Chapter 2,
provided an exciting and unique opportunity determine if an anti-adhesive therapeutic could
provide an alternative, and potentially antibiotic sparing, method to removing UPEC from the
host. The essentiality of the FimH-mannose interaction during UTI prompted the design and
development of orally active, synthetic, small-molecule inhibitors of FimH called mannosides,
which are mannose analogs that are rationally designed to bind within the mannose-binding
pocket of FimH with a high affinity 7. Therefore, I tested the ability of oral mannoside treatment
to target UPEC in both the gut and bladder. My findings show that mannoside treatment
successfully targets a pilus type that is importance for intestinal colonization in mice and
humans. This treatment targets a range of UPEC strains and is successful regardless of host
genetics or microbiota composition. This treatment specifically targets UPEC while leaving the
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surrounding microbiota uninjured and can simultaneously target UPEC in the gut reservoir and at
the site of infection.
Aside from providing a much-needed method to treat individuals infected with drug
resistant uropathogens, a selective treatment, like mannosides, would also reduce the exposure of
entire gut microbiota to antibiotics and thus could curb the development of antibiotic resistant
pathogens. Due to their prevalence worldwide, UTIs are and will continue to be a major
contributor to antibiotic use and resistance. Unfortunately, high rates of UTI and rUTI worldwide
have provided almost persistent exposure of uropathogens to antibiotics, resulting in the
development and swift expansion of UPEC strains encoding resistance genes to one or more
classes of antibiotics. Without effective antibiotics active against uropathogens, UTIs, which are
typically considered low risk infections, will become life threatening and many urological
procedures will carry excessive risk. The need to develop alternative, antibiotic-sparing therapies
to treat individuals with UTI is obvious and pressing.

Main Text
Mannosides target and reduce type 1-expressing UPEC in the gut reservoir
As outlined in Chapter 2, FimH and UclD promote gut colonization and epithelial cell
binding by UTI89. Therefore I conducted a proof-of-concept study designed to eliminate the
UPEC intestinal reservoir in this mouse model using a candidate adhesin-directed therapeutic.
M4284 is a high affinity biphenyl mannoside that inhibits FimH binding to Caco-2 cells (Figure
5). M4284 has a binding affinity for FimH that is ~100,000-fold higher than the natural sugar Dmannose7,8. Pharmacokinetic (PK) analysis showed that after a single oral gavage, M4284
remains present at high concentration in the feces of recipient mice for up to 8 hours (h) (Figure
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10a). In a follow-up experiment, mice were treated with streptomycin, orally gavaged with
UTI89 24 h later, and 3 d later given 3 doses of M4284 (100mg/kg) over a 24 h period (Figure
10b). This dosing regimen was previously used to successfully treat UPEC infection of the
mouse bladder with mannoside9-11. Treatment with M4284 significantly reduced levels of UTI89
in feces as well as cecum and colon by up to 1.5 logs (98% reduction) (Figure 10c). Treating
mice with up to 5 oral doses of M4284 (3 doses administered over 24 h followed by two
additional doses given over the remaining 48 h) reduced the UTI89 population to an even greater
extent (up to 1000-fold) (Figure 11a,b). Moreover, the overall number of UPEC continued to be
lower in mannoside-treated mice up to 5 days after termination of treatment (Figure 11c,d).
While D-mannose blocks FimH binding in vitro at high concentrations (Figure 5), treating mice
with D-mannose had no effect on UTI89 titers in the cecum, colon, and feces (Figure 10d).
Thus, unlike D-mannose, M4284 can effectively compete with the natural receptor at nanomolar
concentrations and prevent FimH-mediated host-pathogen interactions.

Mannosides simultaneously target UPEC in the gut and bladder
There is no mouse model of spontaneous UTI. Moreover, the proximity of the mouse
urethra to soiled bedding and the coprophagic behavior of these animals make creating such a
model challenging. Thus, there is no direct way to test how reducing the UPEC intestinal
reservoir would alter the rate of UTI. However, the established ID50, or minimum number of
UPEC that result in a 50% infection rate in the mouse model of UTI, is 105 CFU12. Decreasing
the inoculation dose of UPEC introduced into the bladder from 108 to 106 CFU resulted in
significantly reduced rates of UTI (Figure 12) suggesting that the 1-1.5 log (or 90-95%)
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mannoside-driven reduction in fecal UPEC levels would reduce the numbers of bacteria
available to be inoculated into the urinary tract and likely reduce the rate of UTI and/or rUTI.
M4284 has low oral bioavailability (<2 %). Thus, >98% of the drug is not absorbed into
the systemic circulation, allowing the compound to exert its effects on type 1-expressing UPEC
in the gut but potentially limiting its effectiveness in the bladder7. To assess whether M4284
could treat an active infection in the bladder while simultaneously reducing the intestinal UPEC
reservoir, mice were orally gavaged with UTI89 and 24 h later given a UTI via transurethral
inoculation. Two days after inoculation of UTI89, 3 doses of M4284 were administered orally
over a 24 h period. Animals were sacrificed 8 h after the last dose and colonization was assessed
(Figure 10e). M4284 significantly reduced UTI89 titers throughout the length of the distal gut
(up to 98%) and in the urinary tract (96-99%) (Figure 10f,g), demonstrating that this mannoside
has sufficient oral absorption to exert its effect in the bladder.

Oral mannoside treatment has minimal effects of the structure of the gut microbiota
To determine whether mannoside treatment affects the gut microbiota structure, we
treated C3H/HeN mice that had not been given streptomycin or infected with UPEC with 3 doses
of M4284 or vehicle alone (10% cyclodextrin). Sequencing bacterial 16S rRNA gene amplicons
generated from fecal samples collected 24 h after cessation of treatment revealed that M4284
produced no significant changes in the overall phylogenetic configuration of the microbiota as
judged by the unweighted UniFrac dissimilarity metric, in contrast to the significant
perturbations produced by treatment with ciprofloxacin, a fluoroquinolone antibiotic (Figure
13a,b, Figure 14a,b). Using this same metric, we found that M4284 treatment did not produce
significant perturbations in bacterial community structure in mice pretreated with streptomycin
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and then colonized with UTI89 (Figure 15). We concluded that M4284 can function to
selectively extirpate UPEC from the gut in our preclinical model. Interestingly, the operon
encoding type 1 pili is carried by nearly every sequenced E. coli strain13 and is highly conserved
throughout the family Enterobacteriaceae14. However, we found that M4284 treatment has no
significant effect on the abundance of Enterobacteriaceae (Figure 14a,b), suggesting that these
bacteria may not be expressing type 1 pili during M4284 exposure or that they reside within

inaccessible intestinal habitats, like biofilms, and are therefore not greatly affected by
mannoside treatment. Further examination of the effects of M4284 treatment on gut
colonization by different species/strains of Enterobacteriaceae is needed to more fully interpret
the significance of these findings.

Mannoside treatment decreases gut colonization by genetically diverse UPEC clinical
isolates
Clinical isolates of UPEC strains are genetically diverse, differing significantly in their
carriage of different pathogenicity associated islands, CUP pili, and resistances to commonlyused antibiotics. Only 60-75% of each UPEC strain’s genome is comprised of a set of shared
genes; fimH is part of this core genome. Therefore, we examined the efficacy of M4284 against a
panel of four diverse UPEC clinical isolates, UTI89, CFT073, EC958, and 41.4p. These isolates
reflect some of the genetic diversity of UPEC; UTI89, EC958, and CFT073 belong to clade B2,
while 41.4p is a member of clade B1. UTI89, EC958, and 41.4p are cystitis isolates, while
CFT073 is a urosepsis isolate. EC958 also encodes resistance genes to a number of clinically
relevant antibiotics. We were able to establish and maintain intestinal colonization of our mouse
model with each isolate tested, and found that M4284 treatment produced similar, statistically
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significant reductions in the levels of each UPEC strain in the cecum, colon, and feces (Figure
13b-f). In each case, the percent reduction in feces or cecum/colon was similar (Figure 16a).

Mannoside treatment reduces UTI89 intestinal colonization in mice of different genetic
backgrounds with diverse gut microbiota communities
Since UTI and rUTI occur in individuals of diverse genetic backgrounds and varied gut
microbiota configurations, we also tested the efficacy of M4284 in both C3H/HeN and C57Bl/6
mice, each from different vendors with different gut microbial community configurations (e.g.
Figure 14c). We found that this treatment reduced the UTI89 intestinal reservoir in each case
tested, with the percentage of UPEC removed from the feces, cecum, and colon not varying
significantly between the three groups of mice (Figure 14f-h, Figure 16b). From these results,
we concluded that M4284 treatment has activity against different UPEC strains in different host
genetic backgrounds and gut microbial community contexts.

Conclusions
As the prevalence of antibiotic-resistant pathogens continues to rise, the need to develop
highly targeted/specific therapeutic approaches has gained increased urgency5,6. Additionally, an
increasing number of studies are finding that disruption of the gut microbiota by orally
administered antibiotics, especially during childhood, may affect its functional properties in
ways that are deleterious to the host, not only in the short term but for more protracted periods of
time2,3. Therefore, developing therapeutic agents, like mannosides, that can specifically target a
pathogen without disrupting the remainder of a microbial community has important ramifications
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not only for UPEC but potentially for other infections, including those caused by
enteropathogens.
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Materials and Methods
Ethics statement
The Washington University Animal Studies Committee approved all procedures used for the
mouse experiments described in the present study. Overall care of the animals was consistent
with The Guide for the Care and Use of Laboratory Animals from the National Research Council
and the USDA Animal Care Resource Guide. For collection of colonic tissues for adhesion
binding studies, mice were sacrificed according to institutional, national and European animal
regulations, using protocols that were also approved by the animal ethics committee of Ghent
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University.

Bacterial strains
CUP operon and adhesin deletions in UTI89 were engineered by replacing the gene(s) of interest
with antibiotic-resistance markers using the λ Red Recombinase system15. Earlier reports
described WT UTI89 and its isogenic fim and fimH mutants12,16 as well as EC95817, 41.4p18 and
CFT07319.

Colonization of mice with UPEC strains
6-week old female C3H/HeN mice were obtained from Envigo or Charles Rivers Labs (CRL). 6week old female C57BL/6 mice were also obtained from Envigo. Animals were maintained in a
single room in our vivarium for no more than 2 days prior to treatment. Prior to and after
treatment all animals received PicoLab Rodent Diet 20 (Purina) ad libitum. All animals were
maintained under a strict light cycle (lights on at 0600h, off at 1800h). For competitive
infections, if a phenotype was observed after testing five mice (1 biological replicate), the
experiment was repeated 1-2 times (total of n=10-16 mice, 2-3 biological replicates). For 16S
rRNA analyses, 4-5 mice were examined (1 biological replicate). For all other experiments, 9-16
mice were tested and the experiment was repeated 2-3 times (2-3 biological replicates).
Exclusion criteria for mice were pre-established; (i) both introduced strains in competitive
infections became undetectable during the course of a 14 day experiment, and (ii) mice died or
lost > 20% of their body weight. No mice in this study met these criteria. Mice were acquired
from indicated vendors and randomly placed into cages (n=5 mice/cage) by employees of
Washington University’s Division of Comparative Medicine (DCM); no additional methods for
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randomization were used to determine how animals were allocated to experimental groups.
Investigators were not blinded to group allocation during experiments.
Animals received a single dose of streptomycin (1000mg/kg in 100 µL water by oral
gavage (PO)) followed 24 h later by an oral gavage of ∼108 CFU UPEC in 100 µl phosphatebuffered saline (PBS). Bladder infections were performed via transurethral inoculation20. UPEC
strains were prepared for inoculation as described previously20. Briefly, a single UTI89 colony
was inoculated in 20 mL of Luria Broth (LB) and incubated at 37°C under static conditions for
24 h. Bacteria were then diluted (1:1000) into fresh LB and incubated at 37°C under static
conditions for 18-24 h. Bacteria were subsequently washed three times with PBS and then
concentrated to ~1x108 CFU per 100 µL for intestinal infections and ~1x108 CFU per 50 µL for
bladder infections.
In all cases, fecal and urine samples were collected directly from each animal at the
indicated time points. Fecal samples were immediately weighed and homogenized in 1 mL PBS.
Urine samples were immediately diluted 1:10 prior to plating. Mice were sacrificed via cervical
dislocation under isofluorane anesthesia and their organs were removed and processed under
aseptic conditions. Intestinal segments (cecum and colon) were weighed prior to homogenization
and plating on LB supplemented with the appropriate antibiotic.

Mannoside Treatment
D-mannose or the mannoside M4284 (which has been characterized in a prior published study11),
were diluted in vehicle (water and 10% cyclodextrin, respectively) and administered to 6 week
old C3H/HeN mice at a dose of 100mg/kg. Control animals were treated with water or 10%
cyclodextrin alone. Unless stated otherwise, three doses of M4284, cyclodextrin, or D-mannose
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were given via oral gavage over 24 hours, with doses administered 8 h apart. Mice were
sacrificed and intestinal tissues were processed for analysis of viable bacteria (CFU) 8 h after the
last dose, unless otherwise noted. To test the effect of M4284 on intestinal UPEC titers after
treatment was terminated, mice were sacrificed 5 days after the last dose of mannoside. To test
the effect of additional doses on M4284 treatment on UPEC titers, mice were given 5 doses of
mannoside; the first 3 doses were administered 8 h apart, followed 12h later by the 4th dose, and
24h later by the 5th dose. Mice were sacrificed 24h after the 5th dose.

Effect of antibiotic exposure on the microbiota
Six week old female C3H/HeN mice from Envigo and CRL were subjected to the following
treatments: (i) none (naïve control mice, Untreated), (ii) three doses of M4284 (100mg/kg; in
10% cyclodextrin) or 10% cyclodextrin given 8 h apart, or (iii) ciprofloxacin (two doses of
15mg/kg given 12 h apart). All doses were given via oral gavage. Five mice were included for
each treatment type (1 biological replicate) and fecal samples were collected prior to treatment
and 24 hours after the last dose of each treatment. Another group of four C3H/HeN mice from
Envigo (1 biological replicate) were pretreated with streptomycin and colonized with UTI89
before recieving treatment with either three doses of M4284 (100mg/kg; in 10% cyclodextrin) or
with 10% cyclodextrin alone; fecal samples were collected prior to treatment but after exposure
to streptomycin and UTI89 and 24 hours after the last dose of each treatment.

Bacterial 16S rRNA sequencing
DNA was extracted by bead beating in extraction buffer [200 mM Tris (pH 8.0), 200 mM NaCl,
20 mM EDTA], 210µL of 20% SDS and 500µL phenol:chloroform:isoamyl alcohol (pH 7.9,
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25:24:1). This crude DNA extract was purified (Qiaquick PCR purification kit) and PCR used to
generate amplicons from the V4 region of bacterial 16S rRNA genes using primers and cycling
conditions described previously21. Amplicons were pooled in equimolar ratios and sequenced on
an Illumina MiSeq instrument (paired end 250 nt reads). Paired V4-16S rRNA sequences were
merged using FLASH software22, demultiplexed, and reads clustered into 97%ID OTUs (2013
Greengenes OTU reference database; QIIME version 1.9.023). A custom database using modified
NCBI bacterial taxonomy was used to train the Ribosomal Database Project (RDP) version 2.4
classifier and assign taxonomy to picked OTUs24. The resulting OTU table was filtered to
include only OTUs found in at least two samples at greater than or equal to 0.1% relative
abundance.

Data Availability
Bacterial V4-16S rRNA datasets have been deposited in the European Nucleotide Archive
(ENA) under accession number PRJEB19121.

Code Availability
No new code was generated for this study. All software was obtained from publicly available
sources; papers describing the software are cited in the text.

Statistical Analysis
The statistical significance of differences between groups in experiments (excluding competitive
infections) was determined by a Mann Whitney U test. Competitive Index (CI) was defined as
(CFU output strain A/CFU output strain B)/(CFU input strain A/CFU input strain B). For
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competitive infections, statistical significance was determined by a Wilcoxon Signed Ranked
test. Statistical analyses were performed using Graphpad Prism 7.
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Figures

Figure 10. Mannoside simultaneously reduces the UPEC intestinal reservoir and treats
UTI. (a) The concentration of M4284 in the feces of mice remains higher than the EC90 of the
drug after a single, oral dose of 100mg/kg. (b) To test the efficacy of M4284 to target UTI89 in
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the mouse intestine, mice were pretreated with streptomycin and colonized with UTI89. Starting
at 3 days post colonization (dpc), mice were given 3 oral doses of M4284 (100mg/kg) or 10%
cyclodextrin (control). (c) UTI89 levels in the feces and intestinal segments were assessed 8 h
after the last dose of mannoside. (d) While mannoside treatment reduced the UTI89 intestinal
load, treatment with D-mannose did not. (e) To determine if M4284 treatment can
simultaneously treat an active UTI and target UPEC in the gut, mice were pretreated with
streptomycin and then received an oral gavage of UTI89. One day later, they were given a UTI
via a transurethral inoculation of this uropathogen. Two days later, they received 3 oral doses of
M4284 (100mg/kg). M4284 reduces UTI89 titers in the gut (f) and urinary tract (g). Bars
represent mean± SEM (a), geometric means ± SD (c,d,f), geometric mean (g) *p<0.05, **p<0.01
by Mann Whitney U test. n=9 mice, 2 replicates (panels f, g), n= 10 mice, 2 replicates (panel d)
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Figure 11. Testing the effects of more prolonged dosing of M4284 and analysis of the
duration of its effects. (a) C3H/HeN mice from Envigo were given two additional doses of
M4284 (5 doses total). (b) Animals treated as in panel (a) show a continued decrease in UTI89
levels in their feces (fecal samples were processed after 3, 4, and 5 doses of M4284), and at the
time of sacrifice in the cecum and colon, compared to control mice treated with vehicle alone
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(10% cyclodextrin). (c,d) The effects of mannoside treatment persist out to 5 days post M4284
exposure. Bars represent geometric mean ± SD, *p<0.05, **p<0.01 by Mann Whitney, n=9-10, 2
replicates (panel b), n=16 mice, 3 replicates (panel d).

Figure 12. The severity of UTI outcome is directly linked to the dose of UTI89 inoculated
into the urinary tract. C3H/HeN mice (Envigo) were given an experimental UTI via
transurethral inoculation of either 108 or 106 CFU of UTI89. The doses were chosen to represent
the reduction observed in intestinal UTI89 titers before and after treatment with the M4284
mannoside. Mice were sacrificed 24 hours after inoculation and UTI89 titers in urine, bladder,
and kidneys were defined by quantifying CFU. Mice receiving the 106 dose of UTI89 had
significantly fewer bacteria in all three biospecimen types, indicating an important relationship
between the number of bacteria introduced into the urinary tract and the severity of UTI
outcome. Bars represent geometric means, **p<0.01, ***p<0.001, ****p<0.0001 by Mann
Whitney U test. n=10 mice, 2 replicates.
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Figure 13. Mannoside treatment has minimal effect on the overall configuration of the fecal
microbiota and targets different human UPEC isolates in mice with different genetic
backgrounds. Mice were given one of the following treatments: (i) M4284 (100mg/kg; 3 doses
over 24 h), (ii) cyclodextrin (10%, Cyclo; 3 doses over 24 h); or (iii) ciprofloxacin (Cipro;
15mg/kg; 2 doses over 24 h). Naïve, untreated mice served as controls (Untreated). Fecal
community structure was defined by sequencing bacterial 16S rRNA gene amplicons. (a) For
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each treatment performed on C3H/HeN mice obtained from Envigo and Charles Rivers Labs, the
change in microbiota configuration was determined by measuring the unweighted UniFrac
distance between samples obtained from each mouse before treatment and 24 h after they
received their last dose (larger UniFrac distance equates to a larger shift in community structure
(beta diversity)). (b) Mice of different genetic backgrounds were colonized by oral gavage with
one of 4 different UPEC strains. At 3 dpc, mice were given 3 doses of M4284 and sacrificed 8 h
after the last dose. (c-f) The intestinal tracts of C3H/HeN mice from Envigo labs were colonized
by each of the genetically diverse human UPEC isolates. (g,h) The ability of M4284 to target
UTI89 in C3H/HeN mice from Charles Rivers Labs (CRL) (panel g) and C57BL/6 mice from
Envigo Labs (panel h) was also assessed. bar = median value. *p<0.05, **p<0.01 (Mann
Whitney U test). n=5 mice, 1 replicate (panel a). Bars represent geometric means ± SD, *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001 (Mann Whitney U test) (panels c-h). n=9-10 animals, 2
replicates (panels c-e, g-h); n=14-15 mice, 3 replicates (panel f)
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Figure 14. 16S rRNA-based comparison of fecal bacterial communities in mice obtained
from Envigo and Charles Rivers Labs and mice of different genetic backgrounds from a
common vendor. (a) C3H/HeN mice were treated with M4284 (100mg/kg, 3 doses over 24 h),
vehicle alone (10% cyclodextrin (Cyclo), 3 doses over 24 h), or ciprofloxacin (Cipro; 15mg/kg, 2
doses over 24 h). Untreated mice served as reference controls. Heatmaps show the effect of each
of the treatments on animals from Charles Rivers Labs (CRL) and Envigo Labs (Envigo). Each
row represents a species-level bacterial taxon, while each column represents a mouse sampled 24
hours after the termination of the indicated treatment. Colored boxes next to the taxon names
indicate species whose relative abundance was significantly changed by Cipro treatment
(p<0.05;Wilcoxon Signed Rank test with FDR correction). Individual comparisons between
untreated and other treatment types did not disclose changes that were statistically significant by
Wilcoxon Signed Rank test with FDR correction. (b) Corresponding fecal samples collected 24 h
after treatments (as shown in Extended Data Figure 8a) were homogenized, diluted serially, and
plated on MacConkey medium. The abundance of bacteria capable of growing on the selective
medium was similar between fecal samples taken from untreated mice and those collected 24
hours after treatment with cyclodextrin and M4284. No colonies were detected from fecal
samples collected 24 hours after ciprofloxacin treatment. n=5 mice, 1 replicate. Bars= median
value, **p<0.001 (Mann Whitney U test). (c) Comparison of the representation of bacterial taxa
in the fecal microbiota of untreated mice obtained from different vendors or representing
different genetic backgrounds. Each row in the heatmap represents a species-level taxon, while
each column represents a mouse of the indicated genetic background from the indicated vendor.
Colored boxes indicate species whose relative abundances were significantly different (p<0.05)
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between all three groups of animals (Kruskal-Wallis test with FDR correction). Rows of each
heatmap were hierarchically clustered according to pair-wise distances using Pearson correlation.
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Figure 15. Bacterial 16S rRNA-based analysis showing that the fecal microbiota of
C3H/HeN mice pretreated with streptomycin and colonized with UTI89 is minimally
altered by M4284 treatment. (a) C3H/HeN mice from Envigo were pretreated with
streptomycin and 24 h later colonized with UTI89 by oral gavage. Three days after inoculation,
mice were treated with 3 doses of M4284 (100mg/kg, 3 doses over 24 h) or vehicle alone (10%
cyclodextrin (Cyclo), 3 doses over 24 h). Fecal samples were collected 24 h after the last dose of
M4284 or vehicle. (b) Heatmap showing the effect of each treatment type. Each row represents a
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bacterial species-level taxon, while each column represents a mouse 24 h after the indicated
treatment. Rows of the heatmap were hierarchically clustered according to pair-wise distances
using Pearson correlation. No treatments produced changes that were statistically significant, as
judged by Wilcoxon Signed Rank test with FDR correction.

Figure 16. The percent reduction in strains by M4284 treatment is similar in mice
colonized with genetically distinct human isolates and in multiple strains of mice colonized
by UTI89. (a) The percent reduction in the indicated UPEC strains from M4284-treated versus
untreated control C3H/HeN mice from Envigo (based on data presented in Fig. 4c-f). (b) These
values were also determined for C3H/HeN mice from Charles Rivers Labs (CRL) and C57BL/6
mice from Envigo (based on data shown in Fig. 4g,h). P values based on Kruskal-Wallis test.
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Chapter 4: Conclusions and Future
Directions
Significance
The steady increase in the number of clinical infections caused by single and multi-drug
resistant bacterial pathogens worldwide highlights the antibiotic crisis we currently face. A
recent review on antimicrobial resistance headed by the British government has indicated that
unless we intervene now, superbugs could kill more people than cancer by 2050.
One manifestation of this crisis are urinary tract infections (UTI) caused by UPEC. Over
a hundred million people are affected by UTIs each year. The global prevalence of UPEC strains
resistant to so-called ‘last-line antibiotics’ like fluoroquinolones and now carbepenems is
increasing at an alarming rate and may foreshadow the end of the road for antibiotics in the
treatment of some patients with UTIs.
The mechanisms by which UPEC cause acute and recurrent UTIs have been studied
extensively; this includes analyses of the roles of chaperone-usher pathway (CUP) pili in
colonization of the bladder and kidneys. While UPEC cause infection in the urinary tract, the gut
is considered to serve as a primary reservoir from which UPEC strains can emerge to colonize
the vagina and peri-urethral area, and subsequently the bladder. However, prior to my thesis
work, little was known regarding the mechanism(s) by which UPEC is able to establish itself in
the gut.
Ultimately, my research has provided significant advances in our knowledge of UPEC
pathogenesis. My work revealed novel E. coli virulence factors (type 1 and F17-like pili) that
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promote intestinal colonization by UPEC. Identification of a role for F17-like pili in intestinal
colonization provides new insights into a previously uncharacterized CUP pilus type.
Identification of a role for type 1 pili in intestinal colonization reveals a new, unexpected
function for a pilus that is essential for infection in the bladder.
I also present a new antibiotic-sparing approach for precision targeting of UPEC in its
intestinal reservoir. If taken to clinical practice, such a treatment would reduce the exposure of
the gut bacterial community to antibiotics. Further, administration of high-affinity mannosides
offers an opportunity to use these compounds as ‘probes’ to identify potential interactions
between other members of the human gut microbial community and mannose-containing glycans
present in the body. Overall, my thesis work provides a powerful example of how anti-microbial
measures can selectively deplete a bacterial pathogen, within the context of the complex gut
microbial community, during acute infection or from its asymptomatic reservoir.

Future Directions
Where is the UclD ligand-binding site?
Based on the structural homology between UclD and F17G, I identified a putative ligandbinding site on the crystal structure of UclD. Further, due to their location within the putative
pocket, I identified six residues that I hypothesize to mediate ligand binding. Moving forward, it
will be important to verify this putative binding site. One way to verify that this is the correct site
would be a mutagenesis study. By mutating each of the hypothesized ‘key’ residues and
assessing their ability to bind to the upper region of the colonic crypts in mouse sections, I would
be able to confirm the location of the binding site. If none of the hypothesized residues result in
the loss of crypt binding, then I would turn to in silico modeling to predict other regions of the
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protein that could contain a ligand-binding site and perform a similar mutagenesis study.
Identifying residues that are critical to ligand binding by UclD is necessary for the creation of
small-molecule ligand antagonists that could be used to target the function of F17-like pili in the
gut.

What is the ligand bound by UclD?
The other essential piece of information required to develop small-molecule ligand
antagonists that target UclD is the identity of the ligand bound by the adhesin. No binding of
UclD is observed to any ligands present on the Center for Functional Glycomics glycan array nor
have we identified a ligand using differential scanning fluorimetry (DSF). However, my work
suggests that the ligand bound by UclD is contained within an O-glycan. Excitingly,
correspondence with Dr. Richard Cummings, the direction of the Center for Functional
Glycomics, has indicated that the center is producing an array containing only structural
variations of O-glycans. This ‘O-glycan’ array will provide a platform tailored toward finding a
potential ligand(s) for UclD. In tandem with the “O-glycan” array, I would also perform in silico
screens to identify ligands that bind virtually within the UclD binding pocket. This type of
analysis would allow us to screen a large number of potential ligands, including those contained
within O-glycans. Any ligands identified via in silico screens or through the ‘O-glycan’ array
would be verified using differential scanning fluorimetry (DSF) and/or Bio-layer Interferometry
(BLI).
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Does oral mannoside treatment effect the commensal E. coli population?
In collaboration with Dr. Jeffrey Gordon and Dr. Andrew Kau, I was able to show that
oral mannoside exposure has minimal effects on the overall structure of the mouse fecal
microbiota. Interestingly, while most Enterobacteriaceae carry the fim operon1-3, mannoside
treatment does not significantly affect the abundance of intestinal Enterobacteriaceae, suggesting
that these bacteria may not be expressing type 1 pili during mannoside exposure or that they
reside within inaccessible intestinal habitats. However, further examination of the effects of
mannoside treatment on gut colonization by different species/strains of Enterobacteriaceae is
needed to more fully interpret the significance of these findings.
Because E. coli makes up a very small portion of the overall microbiota population, 16S
rRNA sequencing is not the most sensitive way to explicitly determine the effect of oral
mannoside treatment on this population. A better way to directly assess the effects of oral
mannoside treatment on the commensal E. coli population would be to examine gnotobiotic mice
harboring defined microbiota communities. After inoculating gnotobiotic mice with defined
microbiota communities (made up of ~10-15 members that represent bacteria associated with the
microbiota of healthy individuals, including different species/strains of Enterobacteriaceae), I
could treat the mice with mannosides and then track the colonization levels of the organisms in
the defined community, including levels of the type 1 pilus-encoding Enterobacteriaceae. This
type of experiment would allow me to directly examine if and/or how mannoside treatment alters
the colonization levels of Enterobacteriaceae. Further, performing this experiment in gnotobiotic
mice that are also colonized intestinally by UPEC prior to oral mannoside treatment would allow
me to determine if mannoside treatment selectively extirpates UPEC while leaving the rest of the
microbiota, including the commensal E. coli strains, untouched.
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One of my hypotheses for why mannoside treatment may not alter type-1 encoding
commensal Enterobacteriaceae is that, unlike UPEC strains, these bacteria do not express type 1
pili in the gut. Examining which CUP pilus types are expressed by commensal E. coli in naïve
mice (that have not been exposed to UPEC or streptomycin, or in mice that have been treated
with streptomycin but not inoculated with UPEC) would begin to test the validity of this
hypothesis. Performing RT-PCR on RNA extracted from feces, cecal content, or colon content
from these mice would be one way to determine which CUP pilus types are being expressed by
commensal Enterobacteriaceae. Additionally, I could inoculate gnotobiotic mice with E. coli
strains that express genetically encoded fluorescent proteins. After treating these mice with a
fluorescently conjugated mannoside, I could perform immunohistochemistry on colon sections
from these mice. This would allow me to simultaneously investigate the expression of type-1 pili
and delineate the localization of E. coli in this mouse model.

What are the mannoside structures that work best to target UPEC in the gut?
Not all available mannoside compounds have the same efficacy in the gut. Out of six
compounds I tested, two compounds reduced UTI89 titers in the intestines, two had no effect,
and two appear to slightly increase UTI89 colonization (Figure 17). Differences in the efficacy
of these compounds could be due to a number of variables, including: bioavailability in the gut
and/or the ability to withstand cleavage by intestinal enzymes. Testing a panel of structurally
distinct mannoside compounds with varied functional groups in our mouse model of UPEC
intestinal colonization would provide some insight into which functional groups and core
structures are the most effective in vivo. Further, analyzing the bioavailability (in the serum,
feces, and urine) of compounds that both successfully and unsuccessfully target intestinal UPEC
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in mice would provide insight into how changing the chemical structures of the compounds alters
the ability of the compound to reach the desired host site.
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Figure 17. Not all mannoside compounds reduce the intestinal UPEC population. C3H/HeN
female mice were pretreated with streptomycin and colonized with UTI89. Starting at 3 days
post UTI89 colonization, mice were given three doses of a mannoside compound (100mg/kg) or
10% cyclodextrin (ctrl) (PO). UTI89 levels in the feces and intestinal tissue were assessed 8
hours after the last dose was given.

Does UPEC bind in the colonic crypts in vivo?
Using immunofluorescence (IF) studies, our collaborators in Han Remaut’s lab found that
the purified lectin domains of FimH and UclD bind to distinct areas within mouse colonic crypts.
This led us to speculate that in vivo, FimH may promote binding to the upper region of the crypts
and surface epithelial cuffs while UclD binds a ligand in the lower crypts. However, several
limitations of this IF study are: 1) binding was assessed with purified protein, rather than with
whole bacteria, and 2) we observed binding to colonic sections that were mounted on microscope
slides, rather than in vivo.
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To address the first point, we chose to examine binding with purified protein, rather than
whole bacteria because using bacteria introduces variables that are difficult to control. For
example, even when we grow UPEC strains under in vitro conditions shown to induce
expression of type 1 pili, we still observe expression of other pili (S and P types), by RNA and
functional analyses3,4. Furthermore, when we genetically engineer the promoter of fimS to remain
in the Phase ON orientation, thus “locking ON” type 1 pilus expression, there is still some
expression of other CUP pilus types4. Thus, obtaining a pure population of UPEC expressing
exclusively one pilus type is not straightforward and complicated by co-expression of other pilus
types. Therefore, we feel that using purified protein is currently the best way to explicitly
characterize the role of a specific pilus type in tissue binding.
Addressing the second limitation of our study, colonic sections were used because
imaging of bacterial binding in vivo is currently limited to techniques like in vivo
bioluminescence imaging, which provides a general idea of the organ where binding is occurring
but cannot provide the cellular detail we gain by imaging tissue sections. However, a major
question derived from our findings that purified protein binds within the colonic crypts is: does
UPEC bind within the crypts in mice and/or humans or is it an artifact of sectioning tissue?
In order to colonize the colonic epithelium, a bacterium first must overcome the
formidable barriers established by the host. The first level of that barrier is the secretion of
antimicrobial peptides (AMPs) by colonic enterocytes. AMPs like β-defensins and cathelicidins
target a wide range of microbes, including gram positive and negative bacteria, fungi, and
viruses, and work to dramatically reduce the number of microbes that can directly interact with
the host surface5. The second major host barrier is the presence of colonic mucus. The mucus
layer is made up of two layers, an outer and inner layer. The outer mucus layer is thicker than the
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inner layer (~100 µm in mice) and is commonly colonized by bacteria6. The outer layer of mucus
is constantly turning over and shedding older mucus into the lumen of the gut, which are then
expelled in the feces. The shedding of the outer mucus layer makes it more difficult for bacteria
to transit through this layer to colonize the inner layer or epithelium. The inner mucus layer is
attached to the colonic epithelium and ranges in thickness from 50 µm in mice to over 100 µm in
humans6. In the past, it was thought that the inner mucus layer is largely devoid of bacterial
colonization. However, recent imaging studies using a fixative that preserves the mucus layer
(Carnoy’s Fixative) identified bacteria in a “significant fraction” of colonic crypts from healthy
mice, indicating that this inner membrane is not sterile7. Interestingly, studies profiling cryptassociated bacterial communities using laser microdissection and sequencing found that this
habitat is often enriched for Proteobacteria capable of aerobic metabolism, like E. coli8.
However, for UPEC to colonize the crypts they must also be able to access and bind a
ligand. Unfortunately, not knowing the ligand for the UclD adhesin limits our ability to
determine if a corresponding ligand is present in the lower crypts. Nonetheless, we can explore
the presence of a mannose containing ligand in this habitat.
Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) are a group of
immunoglobulin-related glycoproteins that are highly mannosylated. Several CEACAM family
members, including CEACAM1, CEACAM6, and CEACAM7, are associated with the normal
colorectal mucosa9. Excitingly, one of these receptors, CEACAM7, has been shown to localize
to the apical surface of highly differentiated epithelial cells in the colorectal mucosa, like those
found in the upper crypts and in epithelial surface cuffs9. The presence of a highly mannosylated
receptor in the same region were we observe FimH binding in our mouse colon sections,
suggests that CEACAM7 might act as a ligand for FimH in vivo. Another CEACAM that has
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been well studied is CEACAM6. While CEACAM6 is expressed at low levels within crypts of
healthy individuals, CEACAM6 levels are elevated in the crypts of patients with colorectal
cancer9,10. One study, using a chronic infection model of CEACAM6 expressing mice, showed
that a B2 E. coli strain isolated from a patient with colon cancer persists to high levels in the gut,
induces colon inflammation, epithelial damages and cell proliferation11. This study did not test
whether colonization, in these mice, was mediated by type 1 pili, however, my findings suggest
that this enhanced intestinal colonization could be mediated by the interaction between type 1
pili and CEACAM6. The ability of FimH to bind to the host intestinal surface in vivo is further
supported by studies finding that patients with the IBD syndrome Crohn’s disease (CD) express
abnormally high levels of CEACAM6 on their ileal epithelium12-15, which is bound by type 1 pili
expressing adherent-invasive E. coli (AIEC).
Altogether, these data suggest that there is a mannose containing ligand in the upper
colonic crypts that could be bound by FimH. However, the thick mucus layer, microbiota, and
plethora of AMPs could make accessing the crypts challenging, particularly in a healthy host.
An interesting way to test the ability of FimH or UclD to bind within the crypts in a more
physiological setting would be to use intestinal spheroid systems. Spheroids take advantage of
proliferative stem/progenitor cells which can be rapidly expanded using conditioned media that
contains signaling proteins that promote cellular growth (Wnt3a, R-spondin and Noggin)16. Upon
differentiation, these cells maintain structural and cellular characteristics of intestinal cells.
When grown on a transwell membrane, spheroids form crypts and functional, polarized
monolayers covered by a secreted mucus16. While spheroids do not completely replicate the
intestinal environment (they lack a microbiota and immune system), they would allow us to
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determine if the adhesins bind to the same locations in human cells and in the presence of a
mucus membrane.

Does the type of intestinal inflammation effect which CUP pili are used for gut
colonization?
The majority of characterized CUP adhesins bind glycan moieties; therefore, any changes
in the intestinal glycan landscape, including altered expression of glycosylated proteins, could
expose ligands for CUP pilus types. Interestingly, previous work has found that the presence of
distinct CUP pilus ligands differs between body sites/habitats and, in some cases, is influenced
by inflammation. For example, Fml pili promote colonization of the bladder during chronic
cystitis, a state of severe, chronic bladder inflammation17. The Fml pilus adhesin, FmlH, binds to
Gal (β1-3) GalNAc, which is only expressed on the surface of the bladder epithelium during
periods of bladder inflammation and remodeling. Accordingly, studies have found that intestinal
disorders and dysbioses have divergent effects on the gut environment, altering the composition
of the microbiota and stimulating distinct immune responses. Interestingly, the inflammatory
state influences the intestinal glycan landscape in the gut of patients with CD. High levels of
intestinal inflammation and/or bacterial dysbiosis cause patients with CD to express abnormally
high levels of CEACAM6 on their ileal epithelium12-15. And as stated before, CEACAM6 is
bound by type 1 pili expressing adherent-invasive E. coli (AIEC).
To determine how distinct types of intestinal inflammation alter the role of CUP pili in
UPEC intestinal colonization, I would examine the ability of individual CUP pilus mutant strains
to compete with the isogenic wildtype strain (UTI89) in IL-10 deficient mice, which are prone to
spontaneous colitis18, or in mice treated with dextran sulfate sodium (DSS). DSS is a chemical
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inducer of colitis and is an accepted mouse model of IBD19,20. DSS, which results in the
recruitment of mainly neutrophils to the gut, has a different inflammatory response than
streptomycin, which results in recruitment of both neutrophils and inflammatory monocytes20-23.
Interestingly, I found that treating C3H/HeN mice with DSS, ad libitum, greatly enhances UPEC
intestinal fitness (Figure 18). In DSS treated mice, UTI89 colonization of the gut occurs for a
more protracted period of time than is observed in streptomycin treated mice. The distinct impact
of these two treatments on the intestinal environment may effect the intestinal glycan landscape
in a way that effects which CUP pilus types are used by UPEC to colonize the intestine.

Figure. 18. Stimulating acute colitis in mice increases UTI89 intestinal colonization.
Streptomycin treated mice were colonized with UTI89. Starting at 7 days post infection (dpi)
mice were provided drinking water supplemented with (red) or without (black) 3% DSS.
Longitudinal fecal (A) and tissue (B) (at 28 dpi) show that DSS treatment enhances UPEC
intestinal colonization. Mann-Whitney U test, **p<0.01, ***p<0.001, ***p<0.0001.

Which CUP pili promote intestinal colonization by other uropathogens and
enteropathogens?
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Like UPEC, other uropathogens (such as Proteus, Enterobacter, and Klebsiella species)
reside in the gut and are able to cause UTI after being shed in the feces and entering the bladder.
However, the bacterial factors that promote intestinal colonization by these uropathogens are
understudied. Each of these bacterial species encode a range of CUP pilus types, some of which
have been shown to promote UTI1. For example, in a mouse model of UTI caused by Klebsiella
pneumoniae, type 1-mediated binding to mannose is indispensible for invasion into urothelial
cells and the formation of IBCs24. Yet, a role for CUP pilus types utilizes by these uropathogens
in the gut has not been explored. This is an interesting question to pursue since many of these
organisms contain CUP pili that are distinct from those carried by UTI89 (for example,
Klebsiella species carry type 3 pili, which are absent in UPEC) and thus may uncover roles for
other uncharacterized pilus types. Further, identifying bacterial factors, like CUP pilus types, that
promote colonization of these non-UPEC uropathogens in the gut is necessary to gain insight
into how these organisms cause disease in the host and may provide targets for anti-adhesive
drugs.
Following the same experimental plan outlined in Chapter 2, I would identify CUP pilus
types that promote intestinal colonization by non-UPEC uropathogens (i.e. creating individual
CUP pilus deletion mutants in each background strain and test their ability to compete with an
isogenic wildtype strain in the streptomycin mouse model). A benefit of this experimental plan is
that it can also be adapted to identify CUP pilus types that promote intestinal colonization by
enteropathogens, like AIEC.
Moreover, identification of intestinally expressed CUP pilus types and their
corresponding ligands for non-UPEC uropathogens or enteropathogens could allow for the
development of ligand antagonists, like mannosides.
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An exciting finding would be identifying a role for type 1 pili in intestinal colonization
by any of the non-UPEC strains, as this would allow us to test the efficacy of mannosides to
target these organisms in the gut.
Perhaps one of the most promising candidates would be Klebsiella species, which carry
type 1 pili and, like UPEC, have been shown to use these pili during UTI24. If type 1 pili promote
Klebsiella intestinal colonization then oral mannoside treatment might be effective at targeting
and reducing the Klebsiella population in both the gut and bladder.
Of note, however, sequence variation in the FimH adhesin between UPEC strains and K.
pneumoniae results in differences in the function of the type 1 pilus in the bladder. In K.
pneumonia, for example, FimH-dependent biofilm formation is inhibited by heptyl mannose, but
not methyl mannose, suggesting that mannose binding to the K. pneumoniae FimH may involve
contacting residues outside of the mannose binding pocket and thus may be more complex than
what occurs in UPEC 24. Changes in the mannose-FimH interaction in Klebsiella might alter the
ability of mannosides to effectively target this organism in the gut. In this case, examining the
ability of mannoside to target and reduce type-1 expressing Klebsiella from binding to guinea pig
red blood cells in vitro (via hemagglutination assays), would be a good start to determine if
mannoside could block FimH activity of Klebsiella species.
Another promising candidate might be AIEC, which use type 1 pili and FimH to bind to
ligands present in the gut. As discussed earlier, AIEC use type 1 pili to bind to CEACAM6 on
the ileal surface during period of intestinal inflammation. To determine if oral mannoside
treatment could target and reduce the AIEC population and potentially reduce intestinal
inflammation in CD patients, I would intestinally colonize mice (either using my streptomycin
model or using IL-10 KO mice) with AIEC and then treat the mice with mannosides. Assessing
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the overall number of AIEC present in treated versus control mice would allow me to examine if
mannosides target AIEC in the gut.
It would also be interesting to determine if mannoside treatment has any effect on the
level or type of intestinal inflammation or the overall structure of the microbiota in mice with
IBD-like syndromes (IL-10 deficient mice or DSS treated mice). Microbial dysbiosis is
associated with the onset and/or severity of IBD in patients. Therefore, if mannoside treatment is
able to reduce the AIEC population in the gut, it might free up niche space or nutrients for
competing organisms and thus alter the microbiota structure in a way that could change the
inflammatory state. Performing cytokine analyses on serum and fecal, cecal, or colon contents
from mice treated with mannosides would provide insight into any effects mannoside treatment
might have on the inflammatory state of mouse models of IBD. Further, 16S rRNA profiling of
the fecal microbiota of these mice would also allow me to determine how oral mannoside
treatment alters the structure of the gut microbiota.

Will oral mannoside treatment work to reduce UPEC in the gut and bladder of humans?
In the end, evaluation of the efficacy and safety of mannosides in the treatment and
prevention of UTI in humans will require clinical trials. I envision that such a trial would enroll
young females (college age) who have a history of chronic/recurrent UTI (3 or more UTIs a
year). Upon experiencing a UTI, these women would be enrolled into the study, an enrollment
urine and fecal sample would be collected, and they would receive treatment with an appropriate
antibiotic. Following this, half of the women would receive long-term daily treatment with an
oral mannoside and half the women would be treated with a placebo control. Longitudinal fecal
collection would take place, allowing us to examine the effect of mannoside on the UPEC
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population in the gut and on the overall structure of the microbiota over time. Rates of recurrent
UTI would also be determined in control vs. mannoside treated individuals.
This study design, which mimics a study that has been done to examine the affects of
drinking cranberry juice on UTI frequency25, would evaluate the efficacy of mannoside treatment
on reducing the rate of recurrent UTIs and its effect on the bacteria present in the gut microbiota.

How will UPEC develop resistance to mannosides?
The ability of bacteria to develop and spread resistance to therapeutics and antibiotics is
causing a major health care crisis. Creating treatments, like mannosides that can selectively
target specific bacteria while leaving the remainder of the microbiota unharmed could help to
slow the development and spread of resistance. However, what are the chances that UPEC will
develop resistance to mannosides, leaving these compounds ineffective?
Bacteria spread resistance through vertical transmission, where mutations that promote
resistance are passed through a population by replication, or through horizontal transmission,
where resistance genes can be swapped from one microbe to another. Regardless of how a
microbe acquires them, resistance genes can function through a number of distinct mechanisms,
including: i) making the cell wall impermeable to the drug, ii) altering the protein bound by the
drug, iii) producing an enzyme(s) that cleaves the drug into an inactive form or degrade it, or iv)
removing the drug from inside the cell via efflux pumps or transporters26. Because mannosides
target a virulence factor expressed on the extracellular surface of UPEC, resistance mechanisms
that prevent the drug from entering or remaining in the bacterial cell are not of concern. While
UPEC might develop or recycle an enzyme to cleave mannosides, this enzyme would need to
differentiate mannosides from mannose or risk cleaving the endogenous ligand for the type 1
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pilus. Altering the protein bound by the mannosides is also possible, however, there are several
reasons why this method of resistance is also not ideal for UPEC.
To develop resistance in this manner, UPEC would need to evolve a FimH protein that is
resistant to mannoside binding but retains its ability to bind mannose. However, type 1 pili and
the FimH adhesin are highly conserved throughout enterobacteriaceae. In fact, the residues that
make up the FimH binding pocket are invariant among all sequenced UPEC strains. Further,
unlike antibiotics that kill or stall bacterial growth, mannosides prevent the function of a nonessential colonization factor, creating less selective pressure to develop resistance to the drug.
Despite all this, the development of resistance to mannosides is certainly possible. It may
be possible to predict the type of genetic mutations that would provide resistance. Random
mutagenesis of the FimH protein followed by screening these mutagenized adhesins for variants
that retain D-mannose binding but are resistant to mannoside might provide a resistant variant

What other bacterial genes are important for UPEC intestinal colonization?
I anticipate that bacterial genes other than CUP pili play a role in UPEC intestinal
colonization. To determine what other genes are important for gut colonization, I would first
want to assess the feasibility of performing a broad unbiased mutagenesis screen of UPEC in the
gut. First, I would test for an intestinal bottleneck using an isogenic set of UTI89 derivatives,
each carrying a unique genetic barcode tag27. A gut colonization bottleneck would preclude my
ability to assess the fitness of large collections of different mutants simultaneously in the gut
model, and thus make the screening of large random mutant library impractical. If there is no
severe gut colonization bottleneck, I would use a transposon mutant library that is already made
in UTI89 and screen for mutations that are defective in gut colonization using TnSeq28.
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Impact and Closing Remarks
In this work, I identify novel E. coli virulence factors (type 1 and F17-like pili) that
promote intestinal colonization. I also present a new antibiotic-sparing approach for precision
targeting of UPEC in its intestinal reservoir. If taken to clinical practice, such a treatment would
reduce the exposure of the gut bacterial community to antibiotics. Further, administration of
high-affinity mannosides offers an opportunity to use these compounds as ‘probes’ to identify
potential interactions between other members of the human gut microbial community and
mannose-containing glycans present in this body habitat that affect their fitness.
Identification of the F17-like pilus in intestinal colonization provides new insights into a
previously uncharacterized CUP pilus type. This data suggest, unexpectedly, that extra-intestinal
pathogenic E. coli, like UPEC, acquired an F17-family CUP from intestinal pathogens, and
evolved it into a unique virulence factor that promotes the establishment and/or maintenance of
an asymptomatic UPEC intestinal reservoir. Identification of genes involved in UPEC
colonization of the gut provide new avenues for therapeutic development and may also provide a
method to stratify UTI patients for epidemiologic studies of recurrent disease risk as well as for
proof of concept clinical studies of the efficacy of CUP-directed treatment regimens: end point
markers for such studies could include reduction/elimination of the intestinal reservoir, treatment
of acute UTI and reduction in rUTI.
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Supplementary Tables
Supplementary Table 1: The phylogenetic relationships between F17 homologs as
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determined by comparing relatedness of bacterial usher gene sequences.

ENA
Sequence
ID
ABE10308
EFJ62248
EFU54800
EGB83651
ESE31717
ADN73675
ALD32943
EDV68536
ELC94190
ELD03594
ELD16276
ELE16801
ELF44072
ELH71006
ELI17337
ELI42231
ELI66860
ELI88553
EQN12131
EQO02162
EQP01733
EQP59624
EQQ43504
EQQ70585
EQQ80267
EQS09284
EQS64201
EQS94171
EQV28377
EQV75237
EQX61640
EQX71663
EQY26881
EQY49990
EQZ33281
ERA15291
ERA29104
ERA85411
ERB29121
ESK12150
ESK22344
ESK23671
ETF18627
EZQ53413
KDG55831
KDN08559
KDO88538
KDT41029

Name of Sequence
Escherichia coli UTI89 putative F17-like fimbrial usher
Escherichia coli MS 200-1 fimbrial usher protein
Escherichia coli MS 153-1 fimbrial usher protein
Escherichia coli MS 60-1 fimbrial usher protein
Escherichia coli A35218R fimbrial usher protein
Escherichia coli UM146 putative F17-like fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F11 fimbrial usher protein
Escherichia coli KTE191 F17-like fimbrial usher
Escherichia coli KTE201 F17-like fimbrial usher
Escherichia coli KTE206 F17-like fimbrial usher
Escherichia coli KTE55 F17-like fimbrial usher
Escherichia coli KTE8 F17-like fimbrial usher
Escherichia coli KTE215 F17-like fimbrial usher
Escherichia coli KTE106 F17-like fimbrial usher
Escherichia coli KTE124 F17-like fimbrial usher
Escherichia coli KTE131 F17-like fimbrial usher
Escherichia coli KTE145 F17-like fimbrial usher
Escherichia coli HVH 4 (4-7276109) F17-like fimbrial usher
Escherichia coli HVH 28 (4-0907367) F17-like fimbrial usher
Escherichia coli HVH 56 (4-2153033) F17-like fimbrial usher
Escherichia coli HVH 77 (4-2605759) F17-like fimbrial usher
Escherichia coli HVH 100 (4-2850729) F17-like fimbrial usher
Escherichia coli HVH 111 (4-7039018) F17-like fimbrial usher
Escherichia coli HVH 112 (4-5987253) F17-like fimbrial usher
Escherichia coli HVH 143 (4-5674999) F17-like fimbrial usher
Escherichia coli HVH 161 (4-3119890) F17-like fimbrial usher
Escherichia coli HVH 171 (4-3191958) F17-like fimbrial usher
Escherichia coli KOEGE 30 (63a) F17-like fimbrial usher
Escherichia coli KOEGE 70 (185a) F17-like fimbrial usher
Escherichia coli UMEA 3185-1 F17-like fimbrial usher
Escherichia coli UMEA 3193-1 F17-like fimbrial usher
Escherichia coli UMEA 3220-1 F17-like fimbrial usher
Escherichia coli UMEA 3244-1 F17-like fimbrial usher
Escherichia coli UMEA 3617-1 F17-like fimbrial usher
Escherichia coli UMEA 3834-1 F17-like fimbrial usher
Escherichia coli UMEA 3955-1 F17-like fimbrial usher
Escherichia coli HVH 228 (4-7787030) F17-like fimbrial usher
Escherichia coli UMEA 3298-1 F17-like fimbrial usher
Escherichia coli UMEA 3290-1 F17-like fimbrial usher
Escherichia coli UMEA 3426-1 F17-like fimbrial usher
Escherichia coli UMEA 3693-1 F17-like fimbrial usher
Escherichia coli HVH 23 (4-6066488) F17-like fimbrial usher
Escherichia coli BIDMC 83 F17-like fimbrial usher
Escherichia coli CHS 69 hypothetical protein
Escherichia coli Outer membrane usher protein htrE precursor
Escherichia coli F17 fimbrial usher
Escherichia coli 3-105-05_S4_C2 type VII secretion system (T7SS), usher family protein
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Percent
Identity
to UTI89
uclC
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100

KDY41355
KEJ39633
KEO42424
KIE65152
KLX09881
KLX89280
KLX98072
KLY02293
KNY00060
KSX67622
KSX77117
KSY42022
KTK66169
KUR86703
KUS25287
KUS30331
KUS39441
KUS56802
KUS66696
KUS97674
KUS99347
KUV71654
KUW51062
KUW91068
KUW97800
KUX04485
KUX29835
KXL01352
KZH53165
KZH65083
KZJ04397
KZP40296
AJM76553
KIE78191
ELC78257
ELI07650
EQW59606
ERA28987
EQV60654
EOV01926
EQP64368
EQV60901
ELL39501
KLX25294
ELD47794
ELE94443
ELF33437
ELF79243
ELH90555
ELJ02444
ELJ33477
EQN27402
EQN57805
EQO39143
EQO97005

Escherichia coli 2-427-07_S4_C2 type VII secretion system (T7SS), usher family protein
Escherichia coli 2-460-02_S1_C3 type VII secretion system (T7SS), usher family protein
Escherichia coli 2-460-02_S1_C2 type VII secretion system (T7SS), usher family protein
Escherichia coli F17 fimbrial usher
Escherichia coli F17-like fimbrial usher
Escherichia coli F17-like fimbrial usher
Escherichia coli F17-like fimbrial usher
Escherichia coli F17-like fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli RS218 F17 fimbrial usher
Escherichia coli RS218 F17 fimbrial usher
Escherichia coli KTE189 F17-like fimbrial usher
Escherichia coli KTE104 F17-like fimbrial usher
Escherichia coli UMEA 3113-1 F17-like fimbrial usher
Escherichia coli UMEA 4075-1 F17-like fimbrial usher
Escherichia coli KOEGE 58 (171a) F17-like fimbrial usher
Escherichia coli KTE195 F17-like fimbrial usher
Escherichia coli HVH 78 (4-2735946) F17-like fimbrial usher
Escherichia coli KOEGE 58 (171a) F17-like fimbrial usher
Escherichia coli J96 putative F17-like fimbrial usher
Escherichia coli F17-like fimbrial usher
Escherichia coli KTE224 F17-like fimbrial usher
Escherichia coli KTE87 F17-like fimbrial usher
Escherichia coli KTE169 F17-like fimbrial usher
Escherichia coli KTE43 F17-like fimbrial usher
Escherichia coli KTE218 F17-like fimbrial usher
Escherichia coli KTE153 F17-like fimbrial usher
Escherichia coli KTE168 F17-like fimbrial usher
Escherichia coli HVH 7 (4-7315031) F17-like fimbrial usher
Escherichia coli HVH 20 (4-5865042) F17-like fimbrial usher
Escherichia coli HVH 38 (4-2774682) F17-like fimbrial usher
Escherichia coli HVH 55 (4-2646161) F17-like fimbrial usher
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100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
100
99.9
100
100
99.9
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7

EQP16163
EQP98545
EQU05851
EQU53211
EQV19738
EQW65711
EQX13871
ERA80937
ERF50184
KDY17150
KIE68021
KUT57088
KUX63359
KZH92368
KZH92802
KZJ70388
KEJ66138
KSW91158
KUX58993
KKA62248
KUS56949
CAD33726
ABG71754
EQW45049
EQW73672
EQW75725
EQY34770
EQY34808
EQT41795
EQT46554
EQU37953
EQW63376
EQU40650
EQQ62500
EQQ82588
EQR09972
EQU89480
EQY63999
KLX39893
KLX42170
KTK78416
KUV23781
KUV45571
KXL00261
KZI73335
EEJ46853
ESD40481
EFJ55400
EFJ93345
ADN49244
ELC24324
ELC59545
ELC84925
ELD42488
ELD59758

Escherichia coli HVH 61 (4-2736020) F17-like fimbrial usher
Escherichia coli HVH 89 (4-5885604) F17-like fimbrial usher
Escherichia coli HVH 197 (4-4466217) F17-like fimbrial usher
Escherichia coli HVH 207 (4-3113221) F17-like fimbrial usher
Escherichia coli HVH 225 (4-1273116) F17-like fimbrial usher
Escherichia coli UMEA 3088-1 F17-like fimbrial usher
Escherichia coli UMEA 3160-1 F17-like fimbrial usher
Escherichia coli HVH 160 (4-5695937) F17-like fimbrial usher
Escherichia coli UMEA 3652-1 F17-like fimbrial usher
Escherichia coli 2-316-03_S4_C3 type VII secretion system (T7SS), usher family protein
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli 3-020-07_S4_C1 type VII secretion system (T7SS), usher family protein
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli 9.1649 fimbrial usher protein
Escherichia coli F17 fimbrial usher
Escherichia coli putative F17-like fimbrial usher
Escherichia coli 536 putative F17-like fimbrial usher
Escherichia coli UMEA 3087-1 F17-like fimbrial usher
Escherichia coli UMEA 3121-1 F17-like fimbrial usher
Escherichia coli UMEA 3121-1 F17-like fimbrial usher
Escherichia coli UMEA 3222-1 F17-like fimbrial usher
Escherichia coli UMEA 3222-1 F17-like fimbrial usher
Escherichia coli HVH 185 (4-2876639) F17-like fimbrial usher
Escherichia coli HVH 185 (4-2876639) F17-like fimbrial usher
Escherichia coli HVH 204 (4-3112802) F17-like fimbrial usher
Escherichia coli UMEA 3113-1 F17-like fimbrial usher
Escherichia coli HVH 204 (4-3112802) F17-like fimbrial usher
Escherichia coli HVH 109 (4-6977162) F17-like fimbrial usher
Escherichia coli HVH 114 (4-7037740) F17-like fimbrial usher
Escherichia coli HVH 117 (4-6857191) F17-like fimbrial usher
Escherichia coli HVH 216 (4-3042952) F17-like fimbrial usher
Escherichia coli UMEA 3257-1 F17-like fimbrial usher
Escherichia coli F17-like fimbrial usher
Escherichia coli F17-like fimbrial usher
Escherichia fergusonii F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli 83972 fimbrial usher protein
Escherichia coli 907892 fimbrial usher protein
Escherichia coli MS 185-1 fimbrial usher protein
Escherichia coli MS 45-1 fimbrial usher protein
Escherichia coli ABU 83972 putative F17-like fimbrial usher
Escherichia coli KTE15 F17-like fimbrial usher
Escherichia coli KTE39 F17-like fimbrial usher
Escherichia coli KTE188 F17-like fimbrial usher
Escherichia coli KTE214 F17-like fimbrial usher
Escherichia coli KTE230 F17-like fimbrial usher
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99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.7
99.8
99.8
99.7
99.6
99.7
99.6
99.6
99.6
99.6
99.8
99.8
99.8
99.8
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.7
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6

ELE78785
ELH41419
ELJ74739
ELJ98001
EOV89522
EQO41248
EQW11354
EQW13192
EQW51065
EQX17451
EQX36137
EQY06764
EQY24271
EQY50557
EQY95004
EQZ06873
EQZ19130
ERA47360
ERA64849
EQX07927
EQX39702
EQX54816
EQY38465
EQY41172
EQZ85064
EQZ91173
ETF28844
EYB58385
KEP00361
KUW14700
KYS70882
ELE03318
ELE37879
ELH68122
ELI71746
EQN00413
EQN45609
EQP06349
EQQ16954
EQQ37550
EQR41036
EQS92042
EQU67332
EQV24276
EQV64639
ESP19911
EQR58384
EQS17497
EQU92514
EQV01012
ERA64868
ERA79243
KZI09905
EQS44918
EQY65807

Escherichia coli KTE86 F17-like fimbrial usher
Escherichia coli KTE183 F17-like fimbrial usher
Escherichia coli KTE88 F17-like fimbrial usher
Escherichia coli KTE99 F17-like fimbrial usher
Escherichia coli KTE89 F17-like fimbrial usher
Escherichia coli HVH 39 (4-2679949) F17-like fimbrial usher
Escherichia coli UMEA 3022-1 F17-like fimbrial usher
Escherichia coli UMEA 3022-1 F17-like fimbrial usher
Escherichia coli UMEA 3097-1 F17-like fimbrial usher
Escherichia coli UMEA 3161-1 F17-like fimbrial usher
Escherichia coli UMEA 3173-1 F17-like fimbrial usher
Escherichia coli UMEA 3208-1 F17-like fimbrial usher
Escherichia coli UMEA 3217-1 F17-like fimbrial usher
Escherichia coli UMEA 3233-1 F17-like fimbrial usher
Escherichia coli UMEA 3337-1 F17-like fimbrial usher
Escherichia coli UMEA 3341-1 F17-like fimbrial usher
Escherichia coli UMEA 3490-1 F17-like fimbrial usher
Escherichia coli UMEA 4076-1 F17-like fimbrial usher
Escherichia coli HVH 156 (4-3206505) F17-like fimbrial usher
Escherichia coli UMEA 3159-1 F17-like fimbrial usher
Escherichia coli UMEA 3175-1 F17-like fimbrial usher
Escherichia coli UMEA 3178-1 F17-like fimbrial usher
Escherichia coli UMEA 3221-1 F17-like fimbrial usher
Escherichia coli UMEA 3230-1 F17-like fimbrial usher
Escherichia coli UMEA 3707-1 F17-like fimbrial usher
Escherichia coli UMEA 3705-1 F17-like fimbrial usher
Escherichia coli HVH 83 (4-2051087) F17-like fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli KTE53 F17-like fimbrial usher
Escherichia coli KTE67 F17-like fimbrial usher
Escherichia coli KTE207 F17-like fimbrial usher
Escherichia coli KTE133 F17-like fimbrial usher
Escherichia coli HVH 2 (4-6943160) F17-like fimbrial usher
Escherichia coli HVH 13 (4-7634056) F17-like fimbrial usher
Escherichia coli HVH 58 (4-2839709) F17-like fimbrial usher
Escherichia coli HVH 92 (4-5930790) F17-like fimbrial usher
Escherichia coli HVH 96 (4-5934869) F17-like fimbrial usher
Escherichia coli HVH 125 (4-2634716) F17-like fimbrial usher
Escherichia coli HVH 169 (4-1075578) F17-like fimbrial usher
Escherichia coli HVH 212 (3-9305343) F17-like fimbrial usher
Escherichia coli HVH 227 (4-2277670) F17-like fimbrial usher
Escherichia coli KOEGE 56 (169a) F17-like fimbrial usher
Escherichia coli HVH 86 (4-7026218) F17-like fimbrial usher
Escherichia coli HVH 132 (4-6876862) F17-like fimbrial usher
Escherichia coli HVH 144 (4-4451937) F17-like fimbrial usher
Escherichia coli HVH 218 (4-4500903) F17-like fimbrial usher
Escherichia coli HVH 220 (4-5876842) F17-like fimbrial usher
Escherichia coli HVH 157 (4-3406229) F17-like fimbrial usher
Escherichia coli HVH 159 (4-5818141) F17-like fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli HVH 153 (3-9344314) F17-like fimbrial usher
Escherichia coli UMEA 3264-1 F17-like fimbrial usher

130

99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6

EQY74298
EQZ69900
EQZ74168
ERA06117
ERA44053
ESJ99313
ESK27829
EYB60166
KEP02518
KHO56518
KUS42725
EQP44047
EQT05774
EQV53030
EQV55245
EQV65664
EQW35180
EQR30454
OAC27962
ELJ78821
EOX21851
ELH20199
ELI19171
EQV28775
EQW14192
EQX15781
EQX72890
ERA29942
KXL21895
KUW45549
AGS60699
AND13784
EKB01574
KSA05685
KGA58547
CAR41290
KGQ15598
KGA89929
KGZ05032
KGZ39655
KSW14302
KSW23593
EEI46422
KGY29288
KGY42554
KGY46341
KXB98825
KKC58837
ETE47402
KUR52793
CAX67955
EHY70493
ENZ87754
ESE91231
ANA20601

Escherichia coli UMEA 3268-1 F17-like fimbrial usher
Escherichia coli UMEA 3687-1 F17-like fimbrial usher
Escherichia coli UMEA 3694-1 F17-like fimbrial usher
Escherichia coli UMEA 3821-1 F17-like fimbrial usher
Escherichia coli UMEA 4207-1 F17-like fimbrial usher
Escherichia coli HVH 98 (4-5799287) F17-like fimbrial usher
Escherichia coli UMEA 3342-1 F17-like fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli HVH 74 (4-1034782) F17-like fimbrial usher
Escherichia coli HVH 172 (4-3248542) F17-like fimbrial usher
Escherichia coli KOEGE 43 (105a) F17-like fimbrial usher
Escherichia coli KOEGE 44 (106a) F17-like fimbrial usher
Escherichia coli KOEGE 61 (174a) F17-like fimbrial usher
Escherichia coli UMEA 3053-1 F17-like fimbrial usher
Escherichia coli HVH 121 (4-6877826) F17-like fimbrial usher
Escherichia coli F17-like fimbrial usher
Escherichia coli KTE94 F17-like fimbrial usher
Escherichia coli KTE185 F17-like fimbrial usher
Escherichia coli KTE194 F17-like fimbrial usher
Escherichia coli KTE113 F17-like fimbrial usher
Escherichia coli KOEGE 30 (63a) F17-like fimbrial usher
Escherichia coli UMEA 3014-1 F17-like fimbrial usher
Escherichia coli UMEA 3160-1 F17-like fimbrial usher
Escherichia coli UMEA 3193-1 F17-like fimbrial usher
Escherichia coli UMEA 4075-1 F17-like fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Proteus mirabilis BB2000 fimbrial usher protein
Proteus mirabilis F17 fimbrial usher
Proteus mirabilis WGLW6 hypothetical protein
Proteus mirabilis F17 fimbrial usher
Proteus vulgaris hypothetical protein
Proteus mirabilis fimbrial usher protein
Proteus mirabilis F17 fimbrial usher
Proteus mirabilis hypothetical protein
Proteus mirabilis F17 fimbrial usher
Proteus mirabilis F17 fimbrial usher
Proteus mirabilis F17 fimbrial usher
Proteus mirabilis F17 fimbrial usher
Proteus mirabilis ATCC 29906 fimbrial usher protein
Proteus mirabilis F17 fimbrial usher
Proteus mirabilis F17 fimbrial usher
Proteus mirabilis F17 fimbrial usher
Proteus mirabilis fimbrial usher protein
Proteus mirabilis F17 fimbrial usher
Salmonella enterica subsp fimbrial usher protein
Salmonella enterica subsp.F17 fimbrial usher
Salmonella enterica putative fimbrial biogenesis usher protein
Salmonella enterica subsp. fimbrial usher protein
Salmonella enterica subsp.Outer membrane usher protein htrE precursor
Salmonella enterica subsp. fimbrial usher protein
Salmonella enterica subsp. diarizonae F17 fimbrial usher
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99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
99.6
97.9
97.9
79.9
79.9
79.9
79.9
79.9
79.9
79.9
79.9
79.9
79.4
79.5
79.5
79.5
79.3
79.2
79.2
79.2
79.2
79.1
79.1
79.1
79.1
79.1
79.1
79.1
79
79.1
58.1
58.1
59.1
59
59
60.6
59.2

ANA24823
ANA29166
ESJ19560
ESE86375
ACT33470
EGI36603
KHG75394
KHI16177
KHI55142
KXQ50743
KIG88168
EID64834
KLG28392
KIG29732
KHI29822
AAA92620
ERA04437
EQO74630
EQS48079
KIO84626
KXL74806
KXL87851
KXM02269
KXM18522
KXM45748
KXN29657
KXN32898
OAC11594
OAC27624
KQJ38281
EKI47004
KHJ08306
EGX03870
EOU64766
KHI17420
KIG71063
KHG81555
KHH99754
KIG38390
KHG83618
ACT33558
EYZ95685
EGI36568
EKH08978
EKH17933
EKH20639
EKH25450
EKH32471
EKH39969
EKH49904
EKH59659
EKH67664
EKH77367
EKH77904
EKH83279

Salmonella enterica subsp. diarizonae F17 fimbrial usher
Salmonella enterica subsp. diarizonae F17 fimbrial usher
Salmonella enterica subsp fimbrial usher protein
Salmonella enterica subsp. fimbrial usher protein
Escherichia coli Vir68 F17 fimbrial usher protein
Escherichia coli TA271 outer membrane usher protein HifC
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli W26 outer membrane usher protein HifC
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli transmembrane protein
Escherichia coli UMEA 3805-1 F17-like fimbrial usher
Escherichia coli HVH 46 (4-2758776) F17-like fimbrial usher
Escherichia coli HVH 153 (3-9344314) F17-like fimbrial usher
Escherichia coli 97.0264 fimbrial usher protein
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli fimbrial transmembrane protein F17a-C
Escherichia coli fimbrial transmembrane protein F17a-C
Escherichia coli F17 fimbrial usher
Escherichia coli N1 transmembrane protein
Escherichia coli F17 fimbrial usher
Escherichia coli STEC_MHI813 outer membrane usher protein hifC
Escherichia coli KTE19 F17-like fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli F17 fimbrial usher
Escherichia coli Vir68 hypothetical protein
Escherichia coli O119:H4 str. 03-3458 deoxyribonuclease HsdR
Escherichia coli TA271 putative fimbrial usher protein
Escherichia coli FRIK920 putative outer membrane usher protein
Escherichia coli PA34 putative outer membrane usher protein
Escherichia coli FDA506 putative outer membrane usher protein
Escherichia coli FDA507 putative outer membrane usher protein
Escherichia coli FDA504 putative outer membrane usher protein
Escherichia coli FRIK1999 putative outer membrane usher protein
Escherichia coli NE1487 putative outer membrane usher protein
Escherichia coli FRIK2001 putative outer membrane usher protein
Escherichia coli PA4 putative outer membrane usher protein
Escherichia coli PA23 putative outer membrane usher protein
Escherichia coli PA49 putative outer membrane usher protein
Escherichia coli PA45 putative outer membrane usher protein
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58.9
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59.8
59.8
59.7
42
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EKH92578
EKH96483
EKI11323
EKI69610
EKJ30920
EKJ31064
EKJ45004
EKJ47884
EKJ49469
EKJ63277
EKJ65985
EKK33136
EKK33786
EKK58486
EKK78428
EKK89063
EKV83394
EKV99677
EKW00030
EKW00417
EKW16280
EKW16942
EKW17713
EKW33758
EKW48481
EKW54352
EKW66086
EKW81431
EKW85444
EKW93747
EKW95043
EKY42416
ELV20957
ELV28748
ELV56195
ELV72838
ELV73067
ELV79731
ELV87097
ELV94460
ELW08784
ELW19147
ELW21161
ELW24342
ELW37584
ELW42989
ELW44766
ERB76857
ERB87400
ERB97963
ERC04184
ERC05409
ERC12039
ERC21172
ERC23962

Escherichia coli TT12B putative outer membrane usher protein
Escherichia coli MA6 putative outer membrane usher protein
Escherichia coli CB7326 putative outer membrane usher protein
Escherichia coli EC1736 putative outer membrane usher protein
Escherichia coli EC1868 putative outer membrane usher protein
Escherichia coli EC1866 putative outer membrane usher protein
Escherichia coli EC1869 putative outer membrane usher protein
Escherichia coli NE098 putative outer membrane usher protein
Escherichia coli EC1870 putative outer membrane usher protein
Escherichia coli FRIK523 putative outer membrane usher protein
Escherichia coli 0.1304 putative outer membrane usher protein
Escherichia coli 5.2239 type VII secretion system (T7SS), usher family protein
Escherichia coli 6.0172 putative outer membrane usher protein
Escherichia coli 8.0586 type VII secretion system (T7SS), usher family protein
Escherichia coli 8.0416 putative outer membrane usher protein
Escherichia coli 10.0821 type VII secretion system (T7SS), usher family protein
Escherichia coli 89.0511 type VII secretion system (T7SS), usher family protein
Escherichia coli 90.2281 type VII secretion system (T7SS), usher family protein
Escherichia coli 90.0039 type VII secretion system (T7SS), usher family protein
Escherichia coli 90.0091 type VII secretion system (T7SS), usher family protein
Escherichia coli 93.0056 type VII secretion system (T7SS), usher family protein
Escherichia coli 93.0055 type VII secretion system (T7SS), usher family protein
Escherichia coli 94.0618 type VII secretion system (T7SS), usher family protein
Escherichia coli 95.0183 type VII secretion system (T7SS), usher family protein
Escherichia coli 96.0428 type VII secretion system (T7SS), usher family protein
Escherichia coli 96.0939 type VII secretion system (T7SS), usher family protein
Escherichia coli 96.0932 type VII secretion system (T7SS), usher family protein
Escherichia coli 97.1742 type VII secretion system (T7SS), usher family protein
Escherichia coli 97.0007 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.0713 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.0672 type VII secretion system (T7SS), usher family protein
Escherichia coli 96.0109 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.0814 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.0815 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.1753 type VII secretion system (T7SS), usher family protein
Escherichia coli ATCC 700728 type VII secretion system (T7SS), usher family protein
Escherichia coli PA11 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.1805 type VII secretion system (T7SS), usher family protein
Escherichia coli PA13 type VII secretion system (T7SS), usher family protein
Escherichia coli PA2 type VII secretion system (T7SS), usher family protein
Escherichia coli PA8 type VII secretion system (T7SS), usher family protein
Escherichia coli 7.1982 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.1781 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.1762 type VII secretion system (T7SS), usher family protein
Escherichia coli 3.4880 type VII secretion system (T7SS), usher family protein
Escherichia coli 95.0083 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.0670 type VII secretion system (T7SS), usher family protein
Escherichia coli B107 type VII secretion system (T7SS), usher family protein
Escherichia coli B26-1 type VII secretion system (T7SS), usher family protein
Escherichia coli B26-2 type VII secretion system (T7SS), usher family protein
Escherichia coli B28-2 type VII secretion system (T7SS), usher family protein
Escherichia coli B28-1 type VII secretion system (T7SS), usher family protein
Escherichia coli B29-1 type VII secretion system (T7SS), usher family protein
Escherichia coli B29-2 type VII secretion system (T7SS), usher family protein
Escherichia coli B36-1 type VII secretion system (T7SS), usher family protein
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ERC27098
ERC35253
ERC44510
ERC44972
ERC50784
ERC69414
ERC84429
ERC89721
ERD03249
ERD03476
ERD04377
ERD18377
ERD19275
ERD20316
ERD33082
ERD34566
ERD41195
ERD50200
ERD51964
ERD53995
ERD66870
ERD67707
ERD68267
ERD80446
ERD83897
ERD87954
ERD94118
ERE09951
ERE24559
ERE35233
ETJ78460
EYV59047
EYV68242
EYV81494
EYV86677
EYW03298
EYW21095
EYW38000
EYW38081
EYW42507
EYW47992
EYW50954
EYW52560
EYW58006
EYW66459
EYW69628
EYW78793
EYW79101
EYW87064
EYW92680
EYX08878
EYX09370
EYX22958
EYX27122
EYX31783

Escherichia coli B36-2 type VII secretion system (T7SS), usher family protein
Escherichia coli B7-1 type VII secretion system (T7SS), usher family protein
Escherichia coli B7-2 type VII secretion system (T7SS), usher family protein
Escherichia coli B93 type VII secretion system (T7SS), usher family protein
Escherichia coli B94 type VII secretion system (T7SS), usher family protein
Escherichia coli type VII secretion system (T7SS), usher family protein
Escherichia coli T234_00 type VII secretion system (T7SS), usher family protein
Escherichia coli 14A type VII secretion system (T7SS), usher family protein
Escherichia coli B104 type VII secretion system (T7SS), usher family protein
Escherichia coli B103 type VII secretion system (T7SS), usher family protein
Escherichia coli 2886-75 type VII secretion system (T7SS), usher family protein
Escherichia coli B105 type VII secretion system (T7SS), usher family protein
Escherichia coli B106 type VII secretion system (T7SS), usher family protein
Escherichia coli B108 type VII secretion system (T7SS), usher family protein
Escherichia coli B109 type VII secretion system (T7SS), usher family protein
Escherichia coli B112 type VII secretion system (T7SS), usher family protein
Escherichia coli B113 type VII secretion system (T7SS), usher family protein
Escherichia coli B114 type VII secretion system (T7SS), usher family protein
Escherichia coli B15 type VII secretion system (T7SS), usher family protein
Escherichia coli B17 type VII secretion system (T7SS), usher family protein
Escherichia coli B40-2 type VII secretion system (T7SS), usher family protein
Escherichia coli B49-2 type VII secretion system (T7SS), usher family protein
Escherichia coli B40-1 type VII secretion system (T7SS), usher family protein
Escherichia coli B5-2 type VII secretion system (T7SS), usher family protein
Escherichia coli B83 type VII secretion system (T7SS), usher family protein
Escherichia coli B84 type VII secretion system (T7SS), usher family protein
Escherichia coli B85 type VII secretion system (T7SS), usher family protein
Escherichia coli type VII secretion system (T7SS), usher family protein
Escherichia coli T1282_01 type VII secretion system (T7SS), usher family protein
Escherichia coli B90 type VII secretion system (T7SS), usher family protein
Escherichia coli ATCC BAA-2192 fimbrial protein
Escherichia coli O157:H7 str. 2009EL2109 fimbrial protein
Escherichia coli O157:H7 str. 2009EL1705 fimbrial protein
Escherichia coli O157:H7 str. K5806 fimbrial protein
Escherichia coli O157:H7 str. F7350 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2312 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2114 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2113 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2112 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2111 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2108 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2109 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2107 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2106 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2105 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2104 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2103 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2101 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2099 fimbrial protein
Escherichia coli O157:H7 str. 08-4169 fimbrial protein
Escherichia coli O157:H7 str. 08-3037 fimbrial protein
Escherichia coli O157:H7 str. 08-3527 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2097 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2098 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2096 fimbrial protein
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EYX41317
EYX42359
EYX49506
EYX49623
EYX53190
EYZ27349
EYZ39043
EYZ50667
EYZ53932
EZA86831
EZA96722
EZB05142
EZB09946
EZB13848
EZB34113
EZB34923
EZB41263
EZB51029
EZB57624
EZB68752
EZB70893
EZB76896
EZB84586
EZB85896
EZB86437
EZB93552
EZB97777
EZC02291
EZC11600
EZC16351
EZC20510
EZC23600
EZC33166
EZC64017
EZC65918
EZC69249
EZC78925
EZC79564
EZC86329
EZC93672
EZC99468
EZD03089
EZD13398
EZD75223
EZD89123
EZE56112
EZE82006
EZF03468
EZQ44480
EZQ53020
KIY27912
KIZ10804
KKF84503
KKK27660
KKY48541

Escherichia coli O157:H7 str. 2011EL-2093 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2094 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2091 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2092 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2090 fimbrial protein
Escherichia coli O157:H7 str. 07-3091 fimbrial protein
Escherichia coli O157:H7 str. 06-4039 fimbrial protein
Escherichia coli O157:H7 str. 06-3745 fimbrial protein
Escherichia coli O55:H7 str. 06-3555 fimbrial protein
Escherichia coli O157:H7 str. F6142 fimbrial protein
Escherichia coli O157:H7 str. F6750 fimbrial protein
Escherichia coli O157:H7 str. F6749 fimbrial protein
Escherichia coli O157:H7 str. F6751 fimbrial protein
Escherichia coli O157:H7 str. F7377 fimbrial protein
Escherichia coli O157:H7 str. H2495 fimbrial protein
Escherichia coli O157:H7 str. G5303 fimbrial protein
Escherichia coli O157:H7 str. K1420 fimbrial protein
Escherichia coli O157:H7 str. K1793 fimbrial protein
Escherichia coli O157:H7 str. K1792 fimbrial protein
Escherichia coli O157:H7 str. K1795 fimbrial protein
Escherichia coli O157:H7 str. K1796 fimbrial protein
Escherichia coli O157:H7 str. K1845 fimbrial protein
Escherichia coli O157:H7 str. K1927 fimbrial protein
Escherichia coli O157:H7 str. K2188 fimbrial protein
Escherichia coli O157:H7 str. K1921 fimbrial protein
Escherichia coli O157:H7 str. K2192 fimbrial protein
Escherichia coli O157:H7 str. K2324 fimbrial protein
Escherichia coli O157:H7 str. K2191 fimbrial protein
Escherichia coli O157:H7 str. K2581 fimbrial protein
Escherichia coli O157:H7 str. K2622 fimbrial protein
Escherichia coli O157:H7 str. K2845 fimbrial protein
Escherichia coli O157:H7 str. K2854 fimbrial protein
Escherichia coli O157:H7 str. K4396 fimbrial protein
Escherichia coli O157:H7 str. K5453 fimbrial protein
Escherichia coli O157:H7 str. K5448 fimbrial protein
Escherichia coli O157:H7 str. K5449 fimbrial protein
Escherichia coli O157:H7 str. K5460 fimbrial protein
Escherichia coli O157:H7 str. K5602 fimbrial protein
Escherichia coli O157:H7 str. K5467 fimbrial protein
Escherichia coli O157:H7 str. K5607 fimbrial protein
Escherichia coli O157:H7 str. K5609 fimbrial protein
Escherichia coli O157:H7 str. K5852 fimbrial protein
Escherichia coli O157:H7 str. K6590 fimbrial protein
Escherichia coli O157:H7 str. K7140 fimbrial protein
Escherichia coli O157:NM str. 08-4540 fimbrial protein
Escherichia coli O157:H7 str. 2009C-4258 fimbrial protein
Escherichia coli O157:H7 str. 2009EL1449 fimbrial protein
Escherichia coli O157:H7 str. 2011EL-2313 fimbrial protein
Escherichia coli O157: str. 2010EL-2045 fimbrial protein
Escherichia coli O157: str. 2010EL-2044 fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli O157:H7 fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli O157:H7 fimbrial protein
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KOZ06857
KOZ10810
KOZ16101
KOZ29806
KOZ48678
KOZ53952
KOZ57012
KOZ72847
KOZ97762
KPH29271
KPH37240
KPH42145
KPP14588
KPP19808
KPP35187
KPP45378
KPP48065
KPP51659
KRQ15005
KYT92957
ADD55863
AEZ39843
AFJ28284
AIG67653
ALH91049
AMW50839
ANE66650
ANG67852
ANG73402
ANG79029
ANW39262
AOD12137
BAB34701
EDU87258
EDU89867
EDU96778
EEC27388
EFW67105
EFX21873
EGD62345
EGD69322
EHU62991
EHU75376
EHU80135
EHU81960
EHU95993
EHV00739
EHV11958
EHV12403
EHV27572
EHV28099
EHV34607
EHV41319
EIN27548
EIN28653

Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli O157:H7 fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli O55:H7 str. CB9615 Putative outer membrane usher protein
Escherichia coli O55:H7 str. RM12579 outer membrane usher protein
Escherichia coli Xuzhou21 putative outer membrane usher protein
Escherichia coli O157:H7 str. EDL933 outer membrane fimbrial usher protein
Escherichia coli O157:H7 fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli O157:H7 fimbrial protein
Escherichia coli O157:H7 fimbrial protein
Escherichia coli O157:H7 fimbrial protein
Escherichia coli O157:H7 fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli O157:H7 str. Sakai putative outer membrane usher protein
Escherichia coli O157:H7 str. EC4501 fimbrial usher protein
Escherichia coli O157:H7 str. EC869 fimbrial usher protein
Escherichia coli O157:H7 str. EC508 fimbrial usher protein
Escherichia coli O157:H7 str. TW14588 fimbrial usher protein
Escherichia coli O157:H7 str. EC1212 putative outer membrane usher protein
Escherichia coli O55:H7 str. 3256-97 putative outer membrane usher protein
Escherichia coli O157:H7 str. 1125 putative outer membrane usher protein
Escherichia coli O157:H7 str. 1044 putative outer membrane usher protein
Escherichia coli DEC3A fimbrial Usher family protein
Escherichia coli DEC3C fimbrial Usher family protein
Escherichia coli DEC3D fimbrial Usher family protein
Escherichia coli DEC3E fimbrial Usher family protein
Escherichia coli DEC4A fimbrial Usher family protein
Escherichia coli DEC4B fimbrial Usher family protein
Escherichia coli DEC4C fimbrial Usher family protein
Escherichia coli DEC4D fimbrial Usher family protein
Escherichia coli DEC4F fimbrial Usher family protein
Escherichia coli DEC5A fimbrial Usher family protein
Escherichia coli DEC5B fimbrial Usher family protein
Escherichia coli DEC5C fimbrial Usher family protein
Escherichia coli FRIK1996 putative outer membrane usher protein
Escherichia coli FDA517 putative outer membrane usher protein
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EIN44971
EIN47324
EIN80149
EIN81204
EIN91451
EIO20073
EIO20293
EIO22332
EIO30655
EIO43631
EIO44995
EIO61076
EIO67789
EIO71388
EIO84707
EIO85331
EIP16971
EIP18683
EIP19202
EIP30962
EIP49382
EIP61961
EIP64455
EIP69570
EIP81532
EKK33536
OAN04922
AAG55651
CTR59674
CTS24352
CTV79962
CUA30582
EFX27205
EKH97331
EFX31563
EKW70091
ERC71947
ERC88804
KOZ32122
EZB38362
KOZ19538
KPO75320
KPP21245
EFX12225
EFX17137
EHU93417
EIO52001
EKI14407
KJJ47841
KOZ57645
KOZ67216
KOZ82091
KOZ82732
KOZ92844
EFX07263

Escherichia coli 93-001 putative outer membrane usher protein
Escherichia coli FRIK1985 putative outer membrane usher protein
Escherichia coli PA10 putative outer membrane usher protein
Escherichia coli PA15 putative outer membrane usher protein
Escherichia coli PA22 putative outer membrane usher protein
Escherichia coli PA31 putative outer membrane usher protein
Escherichia coli PA32 putative outer membrane usher protein
Escherichia coli PA33 putative outer membrane usher protein
Escherichia coli PA40 putative outer membrane usher protein
Escherichia coli PA42 putative outer membrane usher protein
Escherichia coli PA39 putative outer membrane usher protein
Escherichia coli TW10246 putative outer membrane usher protein
Escherichia coli TW11039 putative outer membrane usher protein
Escherichia coli TW07945 putative outer membrane usher protein
Escherichia coli TW10119 putative outer membrane usher protein
Escherichia coli TW09098 putative outer membrane usher protein
Escherichia coli TW14301 putative outer membrane usher protein
Escherichia coli O157:H7 str. TW14313 putative outer membrane usher protein
Escherichia coli EC4421 putative outer membrane usher protein
Escherichia coli EC4422 putative outer membrane usher protein
Escherichia coli EC4436 putative outer membrane usher protein
Escherichia coli EC1738 putative outer membrane usher protein
Escherichia coli EC4437 putative outer membrane usher protein
Escherichia coli EC1734 putative outer membrane usher protein
Escherichia coli EC1863 putative outer membrane usher protein
Escherichia coli 3.4870 type VII secretion system (T7SS), usher family protein
Escherichia coli O157:H7 fimbrial protein
Escherichia coli O157:H7 str. EDL933 putative usher protein
Escherichia coli usher protein
Escherichia coli usher protein
Escherichia coli usher protein
Escherichia coli usher protein
Escherichia coli O55:H7 str. USDA 5905 putative outer membrane usher protein
Escherichia coli 5905 putative outer membrane usher protein
Escherichia coli O157:H7 str. LSU-61 putative outer membrane usher protein
Escherichia coli 96.0107 type VII secretion system (T7SS), usher family protein
Escherichia coli Bd5610_99 type VII secretion system (T7SS), usher family protein
Escherichia coli T924_01 type VII secretion system (T7SS), usher family protein
Escherichia coli fimbrial protein
Escherichia coli O157:H7 str. H2498 fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli O157:H- str. 493-89 putative outer membrane usher protein
Escherichia coli O157:H- str. H 2687 putative outer membrane usher protein
Escherichia coli DEC3F fimbrial Usher family protein
Escherichia coli TW06591 putative outer membrane usher protein
Escherichia coli 5412 putative outer membrane usher protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli O157:H7 str. G5101 putative outer membrane usher protein
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EKI14888
EKK75680
ELW04498
EYY42224
EHU64177
EHV42696
EIN28899
EIN47052
EIN64062
EIN64660
EIN81979
EIO05906
EIO42576
EIP02169
EKH46243
EKI52599
EKI72347
EKJ16694
EKK61703
EKV82226
EKV83788
EKW33566
EKW52543
EKW66188
EKY43968
ELV42265
ELV59010
ELV60235
ERB87602
ERD95759
ERE34518
ERE38404
ERE19084
EKI58398
EKH58316
EHV49910
CTT89937
EFF07341
KOA35398
EGX10205
KJW46289
ELG90062
ANO88318
EHN88119
CDP68350
CDU35541
KHI45262
KUS76798
ELC99050
ELI31921
EQZ68447
EQW90693
EGI22399
KNZ99685
ESA67030

Escherichia coli EC96038 putative outer membrane usher protein
Escherichia coli 10.0869 type VII secretion system (T7SS), usher family protein
Escherichia coli PA48 type VII secretion system (T7SS), usher family protein
Escherichia coli O157:H7 str. 2010C-4979C1 fimbrial protein
Escherichia coli DEC3B fimbrial Usher family protein
Escherichia coli DEC5D fimbrial Usher family protein
Escherichia coli FDA505 putative outer membrane usher protein
Escherichia coli FRIK1990 putative outer membrane usher protein
Escherichia coli PA5 putative outer membrane usher protein
Escherichia coli PA9 putative outer membrane usher protein
Escherichia coli PA14 putative outer membrane usher protein
Escherichia coli PA28 putative outer membrane usher protein
Escherichia coli PA41 putative outer membrane usher protein
Escherichia coli TW09195 putative outer membrane usher protein
Escherichia coli FRIK1997 putative outer membrane usher protein
Escherichia coli PA38 putative outer membrane usher protein
Escherichia coli EC1737 putative outer membrane usher protein
Escherichia coli EC1864 putative outer membrane usher protein
Escherichia coli 8.2524 type VII secretion system (T7SS), usher family protein
Escherichia coli 88.1042 type VII secretion system (T7SS), usher family protein
Escherichia coli 88.1467 type VII secretion system (T7SS), usher family protein
Escherichia coli 95.0943 type VII secretion system (T7SS), usher family protein
Escherichia coli 96.0427 type VII secretion system (T7SS), usher family protein
Escherichia coli 97.0003 type VII secretion system (T7SS), usher family protein
Escherichia coli 97.0010 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.0816 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.1775 type VII secretion system (T7SS), usher family protein
Escherichia coli 99.1793 type VII secretion system (T7SS), usher family protein
Escherichia coli B102 type VII secretion system (T7SS), usher family protein
Escherichia coli B86 type VII secretion system (T7SS), usher family protein
Escherichia coli B89 type VII secretion system (T7SS), usher family protein
Escherichia coli Tx1686 type VII secretion system (T7SS), usher family protein
Escherichia coli 09BKT024447 type VII secretion system (T7SS), usher family protein
Escherichia coli EC1735 putative outer membrane usher protein
Escherichia coli NE037 putative outer membrane usher protein
Escherichia coli DEC5E fimbrial Usher family protein
Escherichia coli usher protein
Escherichia coli B185 outer membrane usher protein
Escherichia coli fimbrial protein
Escherichia coli STEC_MHI813 fimbrial Usher family protein
Escherichia coli fimbrial protein
Escherichia coli KTE146 hypothetical protein
Escherichia coli fimbrial protein
Escherichia coli TA124 hypothetical protein
Escherichia coli D6-113.11 Putative outer membrane usher protein
Escherichia coli D6-113.11 Putative outer membrane usher protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli KTE193 hypothetical protein
Escherichia coli KTE112 hypothetical protein
Escherichia coli UMEA 3671-1 hypothetical protein
Escherichia coli UMEA 3124-1 hypothetical protein
Escherichia coli M718 putative fimbrial usher protein
Escherichia coli fimbrial protein
Escherichia coli 113290 fimbrial usher protein
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43.7
43.7
43.7
43.7
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.6
43.8
41.9
43.6
43.6
43.6
43.5
43.5
43.4
43.3
43.4
43.7
43.7
43.8
43.8
43.6
43.6
43.7
43.9
43.5
43.5
43.7

KFD74598
ESM39020
KYT01105
KYU52385
EHN96543
EQZ93543

Escherichia coli fimbrial protein
Escherichia coli BWH 32 hypothetical protein
Escherichia coli fimbrial protein
Escherichia coli fimbrial protein
Escherichia coli E101 hypothetical protein
Escherichia coli UMEA 3718-1 hypothetical protein

Supplementary Table 2: The carriage of F17-like pili in rUTI UPEC strains.

139

43.7
43.6
43.8
43.8
43.8
43.7

Strain

Pathotype

Clade

BioProject

F17-like
Carriage

536

UPEC

B2

PRJNA16235

Yes

11128

EHEC

B1

PRJDA32513

11368

EHEC

B1

PRJDA32509

12009

EHEC

B1

PRJDA32511

55989

EAEC

B1

PRJNA33413

2009EL-2050

EHEC

B1

PRJNA81097

2009EL-2071

EHEC

B1

PRJNA81099

2011C-3493

EHEC

B1

PRJNA81095

ABU 83972

ABU

B2

PRJNA38725

APEC O1

APEC

B2

PRJNA16718

APEC O78

APEC

B1

PRJNA184588

ATCC 8739

Commensal

A

PRJNA18083

BL21(DE3)

Lab Strain

A

PRJNA20713

BW2952

Lab Strain

A

PRJNA33775

CB9615

EPEC

E

PRJNA42729

CE10

NMEC

F

PRJNA63597

CFT073

UPEC

B2

PRJNA313

clone D i14

UPEC

B2

PRJNA52023

clone D i2

UPEC

B2

PRJNA52021

DH1

Lab Strain

A

PRJDA52077

DH10B

Lab Strain

A

PRJNA20079

E2348/69

EPEC

B2

PRJEA32571

E24377A

ETEC

B1

PRJNA13960

EC4115

EHEC

E

PRJNA27739

ED1a

Commensal

B2

PRJNA33409

EDL933

EHEC

E

PRJNA259

H10407

ETEC

A

PRJEA42749

HS

Commensal

A

PRJNA13959

IAI39

UPEC

F

PRJNA33411

IHE3034

NMEC

B2

PRJNA43693

K12 MG1655

Commensal

A

PRJNA40075

LF82

AIEC

B2

PRJNA33825

NRG 857C

AIEC

B2

PRJNA41221

REL606

Lab Strain

A

PRJNA18281

RM12579

EPEC

E

PRJNA68245

S88

Commensal

B2

PRJNA33375

SE11

Commensal

B1

PRJNA18057

SE15

Commensal

B2

PRJDA19053

SMS-3-5

Environmental

F

PRJNA19469

TW14359

EHEC

E

PRJNA30045
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Yes

Sample Time
Point**

UM146

AIEC

B2

PRJNA50883

UMNK88

ETEC

A

PRJNA42137

UTI89

UPEC

B2

PRJNA16259

W

Lab Strain

B1

PRJNA48011

W3110

Lab Strain

A

PRJNA16351

Xuzhou21

EHEC

E

PRJNA45823

2.1a*

UPEC

A

PRJNA269984

2.2r*

UPEC

D

PRJNA269984

Yes
Yes

Enrollment UTI
Different-strain
rUTI

5.1a*

UPEC

B1

PRJNA269984

5.2p*

UPEC

B2

PRJNA269984

Enrollment UTI

5.3r*

UPEC

B2

PRJNA269984

9.1a*

UPEC

D

PRJNA269984

Enrollment UTI

9.2p*

UPEC

B1

PRJNA269984

9.3r*

UPEC

B1

PRJNA269984

Prior to Recurrence
Different-strain
rUTI

11.1a*

UPEC

A

PRJNA269984

Enrollment UTI

11.2p*

UPEC

A

PRJNA269984

Prior to Recurrence

Yes
Yes

Prior to Recurrence
Different-strain
rUTI

11.3r*

UPEC

A

PRJNA269984

12.1a*

UPEC

B2

PRJNA269984

Yes

Enrollment UTI

12.2p*

UPEC

B2

PRJNA269984

Yes

Prior to Recurrence

PRJNA269984

Yes

Same-strain rUTI
Same-strain rUTI

12.3r*

UPEC

B2

Same-strain rUTI

12.4r*

UPEC

B2

PRJNA269984

Yes

17.1a*

UPEC

B2

PRJNA269984

Yes

Enrollment UTI

17.2p*

UPEC

B2

PRJNA269984

Yes

Prior to Recurrence

PRJNA269984

Yes

Same-strain rUTI
Enrollment UTI

17.3r*

UPEC

B2

20.1a*

UPEC

B2

PRJNA269984

Yes

20.2r*

UPEC

B2

PRJNA269984

Yes

Same-strain rUTI

20.3r*

UPEC

B2

PRJNA269984

Yes

Same-strain rUTI

PRJNA269984

Yes

Enrollment UTI
Prior to Recurrence

21.1a*

UPEC

B2

21.2p*

UPEC

B2

PRJNA269984

Yes

21.3r*

UPEC

B2

PRJNA269984

Yes

Same-strain rUTI

26.1a*

UPEC

B2

PRJNA269984

Yes

Enrollment UTI

PRJNA269984

Yes

Prior to Recurrence

Yes

Same-strain rUTI

26.2p*

UPEC

B2

26.3r*

UPEC

B2

PRJNA269984

31.1a*

UPEC

B1

PRJNA269984

Enrollment UTI

31.2p*

UPEC

B1

PRJNA269984

31.3r*

UPEC

B2

PRJNA269984

Prior to Recurrence
Different-strain
rUTI

34.1a*

UPEC

B2

PRJNA269984

Yes

Enrollment UTI

34.2r*

UPEC

B2

PRJNA269984

Yes

Same-strain rUTI

35.1a*

UPEC

B2

PRJNA269984

Yes

Enrollment UTI

PRJNA269984

Yes

Prior to Recurrence

35.2p*

UPEC

B2
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35.3r*

UPEC

B2

PRJNA269984

Yes

Same-strain rUTI

41.1a*

UPEC

B2

PRJNA269984

Yes

Enrollment UTI

41.2p*

UPEC

B2

PRJNA269984

Yes

Prior to Recurrence

Yes

Same-strain rUTI

41.3r*

UPEC

B2

PRJNA269984

41.4p*

UPEC

B1

PRJNA269984

41.5r*

UPEC

B1

PRJNA269984

56.1a*

UPEC

B1

PRJNA269984

56.2r*

UPEC

B2

PRJNA269984

56.3r*

UPEC

B2

PRJNA269984

Prior to Recurrence
Different-strain
rUTI
Yes
Yes

Enrollment UTI
Different-strain
rUTI
Same-strain rUTI

* Collected during a previous longitudinal study on recurrent UTI (ref. 18)
** Sample time point as defined in [REF]

Supplementary Table 3: UclD X-ray collection and refinement statistics
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HRUclD

LD

UclDLD

(5NWP)

(5VQ5)

P21

P212121

a, b, c (Å)

31.0, 91.9, 64.9

39.0, 58.6, 175.1

α, β, γ (°)

90.0, 96.5, 90.0

90.0, 90.0, 90.0

Resolution (Å) a

91.87 – 1.05 (1.111.05)

55.60-1.6 (1.661.60)

Rmerge a

0.079 (0.336)

0.05 (0.43)

I/σ(I) a

11.9 (2.1)

17.68 (1.43)

CC1/2 a

99.6 (86.0)

0.998 (0.659)

Completeness (%)a

88.6 (43.8)

99.97 (99.98)

5.0 (2.0)

2.0 (2.0)

Resolution (Å)

91.87 - 1.05

55.60 - 1.60

No. reflections

144393

108142

Rwork / Rfree

0.118 / 0.143

0.172 / 0.218

No. atoms

6890

3289

Protein

6223

2804

Iodide

/

6

Sulphate

1

/

662

479

Protein

10.7

22.4

Iodide

/

62.6

Data collection
Space group
Cell dimensions

Redundancy a

Refinement

Water
B factors

143

Sulphate

11.0

/

Water

23.9

36.2

Bond lengths (Å)

0.028

0.002

Bond angles (°)

2.281

0.58

R.m.s. deviations

Number of crystals for each structure should be noted in footnote.
a

Values in parentheses are for highest-resolution shell.
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